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Abstract !
Parenteral nutrition (PN) serves as an important therapeutic modality that is used in adults, 
children, and infants for a variety of indications. The appropriate use of this complex therapy 
aims to maximize clinical benefit while minimizing the potential risks for adverse events. 
Complications can occur as a result of the therapy and as the result of the PN process. These 
consensus recommendations are based on practices that are generally accepted to minimize 
errors with PN therapy, categorized in the areas of PN prescribing, order review and verification, 
compounding, and administration. These recommendations should be used in conjunction with 
other A.S.P.E.N. publications, and researchers should consider studying the questions brought 
forth in this document. !!
Introduction !
Parenteral nutrition (PN) serves as an important therapeutic modality that is used in adults, 
children, and infants for a variety of indications. The appropriate use of this complex therapy 
aims to maximize clinical benefit while minimizing the potential risk for adverse events. Despite 
being classified and acknowledged as a high-alert medication,1 only 58% of organizations have 
precautions in place to prevent errors and patient harm associated with PN.2 Complications can 
occur as a result of the therapy and as the result of the PN process. These recommendations are 
based on practices that are generally accepted to minimize errors with PN therapy. However, the 
broad range of healthcare settings in which PN administration occurs—from critical care to 
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home care—raises the potential for disparities to exist in the knowledge and skills of the 
healthcare professionals responsible for PN prescribing, review, compounding, and 
administration. Regardless of the setting or the number of patients treated in a given facility, the 
classification of PN as a high-alert medication requires healthcare organizations to develop 
evidence-based policies and procedures related to PN. Conceptually, the American Society for 
Parenteral and Enteral Nutrition (A.S.P.E.N.) recommends use of the standardized process, 
which includes clinicians with expertise in the area of nutrition support.3 !
During the past few years, many circumstances and incidents have threatened the safety of 
patients receiving PN as an important therapy. In light of the need to revise A.S.P.E.N.’s Safe 
Practices for Parenteral Nutrition guidelines and to publicly address the safety of PN 
prescribing, compounding, and delivery, A.S.P.E.N. leaders hosted a multiorganizational safety 
summit on September 23, 2011. This summit brought together 46 key stakeholders to identify 
processes to improve the safety of prescribing, preparing, and delivering PN to patients across a 
variety of healthcare settings.4 Findings from this summit guided the A.S.P.E.N. PN Safety Task 
Force to develop safety consensus recommendations. !
In an attempt to answer as many questions about PN safety as possible, this Task Force, in 
partnership with the A.S.P.E.N. Clinical Practice Guidelines Editorial Board PN workgroup, 
developed many clinical questions still unanswered in existing documents. The workgroups were 
divided into two segments, each responsible for specific tasks. The first group developed 
questions that could be answered with a high level of confidence using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) process (the process by 
which the A.S.P.E.N. Clinical Guidelines are developed).5 The second group developed questions 
for which the level of evidence in the literature did not support any GRADE-level 
recommendations, meaning that consensus recommendations would depend on expert opinion. 
This paper addresses clinical concerns that impact PN safety for which current literature does not 
provide GRADE-level evidence and provides consensus recommendations for safe PN practice 
and future research based on expert opinion. These recommendations are not clinical guidelines 
as defined by A.S.P.E.N.6 The need to deliver practice information to clinicians, even when it is 
of a consensus nature from practice experts, remains an important role of A.S.P.E.N. 
Redundancies were deliberately built into this document between sections for users who may 
only view individual sections based on their practice area. Reviewers of this paper included the 
A.S.P.E.N. Clinical Practice Committee, Dietetics Practice, Medical Practice, Nutrition Support 
Nurses, and Pharmacy Practice Sections, as well as clinical content experts outside of the 
organization. This document was also reviewed and approved by the A.S.P.E.N. Board of 
Directors. The questions to be answered with the Clinical Practice Guidelines GRADE process, 
listed in Appendix 1, will be addressed by a separate workgroup and published separately. This 
document should be used in conjunction with those guidelines. !
Similar to A.S.P.E.N.’s Standards of Practice documents, the following terminology is used with 
each recommendation to indicate the level of evidence and strength of consensus reached for 
each statement. 
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!
“Shall”: Indicates that the recommendation is to be followed strictly.  !
“Should”: Indicates that among several possibilities, one is particularly suitable, without 
mentioning or excluding others, or that a certain course of action is preferred, but not 
necessarily required.  !
“May”: Indicates a course of action that is permissible within the limits of recommended 
practice.  !
The recommendations within this document are intended for discussion and adoption over time 
by organizations and individual professionals involved in the routine care of patients requiring 
PN. These recommendations are not intended to supersede the judgment of the healthcare 
professional based on the circumstances of the individual patient. Although the substantial 
focus of these recommendations is on institutional settings, many of the safety issues exist across 
other patient-care settings. Concerns that are unique to home care are also addressed where 
appropriate. In every clinical setting, it is the responsibility of the prescriber, pharmacist, nurse, 
dietitian, and nutrition support team to recognize and report all PN-related medication errors, 
whether or not they reach the patient. This allows the medication safety officer/committee to 
review and address these events periodically with the committee or individuals having oversight 
of PN. !
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Prescribing and Communicating the Parenteral Nutrition Order !
Background !
N is a complex prescription therapy associated with significant adverse effects. Deaths have 
occurred when safe practice guidelines were not followed.1 Appropriate and safe prescribing and 
ordering of PN is a critical first step and an essential component of the PN use process. The safe 
prescribing of PN requires a thorough knowledge of protein and energy requirements, 
macronutrients, micronutrients, fluid homeostasis, and acid-base balance. The prescriber shall be 
well versed in the appropriate indications for PN, basics in sterility and infection control, as well 
as vascular access devices (peripheral and central) and their associated complications. Safe 
prescribing of PN begins with PN-specific interdisciplinary education and institutional policies 
focused on writing clear PN orders. Furthermore, there shall be clear means of communication 
among physicians, physician extenders/mid-level providers (eg, nurse practitioners, physician 
assistants), dietitians, pharmacists, and nurses involved in this process. This section provides 
guidance and suggestions for healthcare institutions to adopt in order to promote safe prescribing 
of PN. Many of these recommendations have been adapted from literature of another high-alert 
therapy: cancer chemotherapy.2-4 !
Question: Prescribing 1–2 (P1–P2) !
(P1) Does a standardized process for PN prescribing increase clarity and reduce PN-related 
errors? (P2) What are the essential elements of a PN order that minimize errors? !
Recommendations !
1. Healthcare organizations shall use a standardized process for PN management, and this 
process shall include clinicians with expertise in the area of nutrition support, preferably 
from multiple disciplines.5,6 
a. Healthcare organizations shall develop written policies and procedures for all aspects of 
PN therapy in the manner described in the A.S.P.E.N. Safe Practices for Parenteral 
Nutrition.1 
b. The patient and caregivers shall be informed of the risks and benefits associated with PN. 
c. A comprehensive PN education program and competency assessment shall be developed 
for healthcare professionals who are involved in the care of patients receiving PN 
therapy, and competency should be assessed at least annually.4 
d. Healthcare organizations shall have a written policy addressing credentials, training, and 
competency certification(s) required of clinicians who prescribe PN.4 
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2. The primary healthcare team, in collaboration with nutrition support professionals, shall 
evaluate, clearly define, and accurately document the patient’s medical problem(s) and 
indication(s) for PN. 
a. The patient shall have an appropriate indication for PN therapy based on published 
guidelines and evidence for the use of PN, which shall be documented in the medical 
record.1  
b. The healthcare team shall confirm that the patient has appropriate intravenous (IV) 
access for PN prior to prescribing PN therapy.1 
c. The indication(s) for PN and appropriate IV access shall be included on the PN order 
(see section 4 and Table 1).1 
3. The primary healthcare team, in collaboration with nutrition support professionals, shall 
specify and document the therapeutic goal(s) of PN therapy.  
a. Appropriate energy and protein goals shall be determined for the patient’s condition 
based on published guidelines and evidence.1 
b. Appropriate parameters and frequency of monitoring shall be determined for the patient’s 
condition to assess efficacy, detect and prevent complications, evaluate changes, and 
document outcomes.1  
c. Appropriate monitoring parameters for PN shall include fluid requirements, serum 
electrolyte concentrations, serum glucose concentrations, hepatic function, renal 
function, serum triglyceride concentrations, and signs or symptoms of vascular access 
device complications.1  
d. Therapeutic goals should be established for PN, including end points, response to 
treatment, and treatment failure. 
4. PN shall be prescribed using a standardized PN order format and review process applicable 
to patients of every age and disease state within a healthcare organization.1,6  
a. Standardized electronic PN orders (eg, a computerized prescriber order entry [CPOE] 
system) should be used to prescribe PN for all patients.1,7-9 Handwritten orders to 
prescribe PN should be avoided due to potential for error. Verbal and telephone orders for 
PN should be avoided.  
b. Clinical decision support should be available within electronic PN orders to alert and 
prevent prescribers from ordering doses of macronutrients, micronutrients, and/or 
medications that exceed recommended/safe clinical limits or that exceed limits of 
compatibility (eg, hard limits when maximum concentrations have been exceeded).1,7,8  
c. When a CPOE system is not available, PN should be prescribed using a standardized 
order template as an editable electronic document in order to avoid handwritten orders.  
d. PN order templates shall be designed so they are clear and easily understood by all 
healthcare professionals involved in the care of patients receiving PN.1 
e. Table 1 lists components that shall be included on the PN order.1,4  
f. All PN order templates should include the required components listed in the sequence in 
Table 1. This sequence should match the PN labels as well. See Figure 1 and Figure 2 for 
PN Order Templates.  
g. In the event of a product shortage, PN component conservation and allocation strategies 
should include the A.S.P.E.N. parenteral nutrition shortage considerations for 
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multivitamins, trace elements, IV fat emulsions (IVFE), amino acids, electrolyte/
minerals, and cysteine,10-15 and the PN order format should be updated accordingly. 
Multivitamins shall be prescribed daily in PN admixtures. When multivitamin products 
are not available, thiamine, ascorbic acid, pyridoxine, and folic acid should be prescribed 
daily.10  
h. All PN ingredients shall be ordered in amounts per day (eg, for adult patients) or 
amounts per kilogram per day (eg, pediatric and neonatal patients) rather than in amounts 
per liter, percent concentration, or volume.1 Amount per day refers to macronutrients in 
grams per day, and micronutrients in mEq, mmol, mcg, or mg per day. Electrolytes shall 
be ordered as the complete salt form rather than the individual ion.1 Each individual 
macronutrient and micronutrient ordered shall be listed with its corresponding dose.1 If 
available, the total ion amounts and concentrations may be reported or displayed to the 
prescriber within the PN order.  
i. The PN order template in CPOE systems should display current patient monitoring 
values and their date and time of entry to include parameters such as laboratory values, 
temperature, weight, etc.  
j. The PN order template should contain the full generic name for each ingredient.1,4 
Proprietary names should only be used when multiple products exist and/or when the 
proprietary name may assist in identifying unique properties of the specific dosage form 
(eg, inherent electrolytes in amino acid formulations, fatty acids in IVFE).4 Any 
abbreviations shall follow The Joint Commission standards on abbreviations.4,16 
Abbreviations on the Institute for Safe Medication Practices (ISMP) list of error-prone 
abbreviations, symbols, and dose designations shall not be used.17  
k. The PN order should include related orders for routine care, laboratory tests, and relevant 
monitoring parameters.1  
l. Prescribing a PN formulation that includes non-nutrient medications should be avoided. 
When no other reasonable alternatives exist, non-nutrient medications shall only be 
included on the PN order if data support compatibility/stability.1  
m. Healthcare organizations should develop policies and/or protocols to allow modification 
of PN orders when potential incompatibilities may exist (eg, incompatibilities associated 
with calcium and phosphate salts, adjustment of IVFE dosing when it is not expected to 
be stable as a total nutrient admixture [TNA] [ordering IVFE separately or adjusting 
IVFE dosing such that the daily dose achieves minimum concentration for stability]).1 
All PN order modifications shall be communicated to the healthcare team and 
documented in the medical record. PN orders shall be signed by a licensed prescriber 
who has been credentialed by the healthcare organization to prescribe PN.4  
n. PN orders should be prescribed with a time limitation to allow for appropriate patient 
evaluation at predetermined intervals based on clinical status and required level of care.
1-4  
o. For optimal safety, PN orders should be prescribed and transmitted when supported by 
properly trained personnel who regularly perform this task. This is usually done during 
daytime hours.18  
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5. Institutions shall create a home PN order template/format that provides a safe plan for 
multiple days of therapy. The prescription for home PN therapy should be written in a format 
that specifically reflects trends in laboratory values and previous days of PN therapy. An 
institutional daily PN order format should not be used as a home PN prescription.  
6. The most appropriate nutrition modality, in collaboration with nutrition support 
professionals, should be prescribed for the patient. Healthcare organizations should 
determine the most appropriate types of PN formulation(s) for their patient population(s) (eg, 
standardized compounded, standardized commercial [premixed] PN products, or customized 
compounded PN admixtures) or methods of delivery (eg, dextrose/amino acid vs total 
nutrient admixtures) and should develop criteria for each formulation that will be used in 
their patients.19 !
Table 1. Required Components for PN Orders and Preferred Sequence. !
Components for the PN Order !
Patient Information 
 Patient identifiers (patient name, medical record number or other unique identifiers, birth date/age, patient  
 location) 
 Patient location (home address for home PN patients) 
 Allergies and reactions 
 Height and dosing weight (metric) 
 Diagnosis(es)/indication(s) for PN 
 Vascular access device/location 
 Administration date/time !
PN Ingredients (should match PN label) 
 Amino acids 
 Dextrose 
 IVFE 
 Sodium phosphate 
 Sodium chloride 
 Sodium acetate 
 Potassium phosphate 
 Potassium chloride 
 Potassium acetate 
 Magnesium sulfate or magnesium chloride 
 Calcium gluconate 
 Multivitamins 
 Trace elements 
 Additives (eg, cysteine, regular insulin) as clinically appropriate and compatible !
PN Instructions 
 Total volume, infusion rate, start and stop times, cycle information 
 Prescriber and contact information !
Rationale !
PN is a complex prescription therapy with many potential safety concerns. The World Health 
Organization (WHO) advocates a systematic approach to prescribing in order to improve quality 
and minimize errors.2 Pollock and colleagues described considering drug costs and using  !
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Figure 1. Parenteral Nutrition Order Template: Adult Patient.  !
computer technology when prescribing medications.3 These approaches provide an excellent 
template for the clinician prescribing PN. The A.S.P.E.N. Safe Practices for PN document 
describes the benefits of using a standardized PN ordering process and recommends components 
that should be included on a PN order template (mandatory, strongly recommended, and worthy 
of consideration).1 Like PN, chemotherapy is a class of complex prescription medications with 
critical safety concerns. The American Society of Clinical Oncology and Oncology Nursing 
Society developed Chemotherapy Administration Safety Standards in the outpatient setting in 
2009,20 with revisions to expand these to the inpatient setting in 2011.4 The concepts in these 
safety standards are consistent with the A.S.P.E.N. Safe Practices for PN. We recommend that 
healthcare organizations and clinicians adopt these standards and guidelines when creating 
policies for ordering/prescribing PN.1-4 !
Standardized order formats for PN incorporating prescriber guidelines can provide education that 
can lead to reduced prescribing errors, improved efficiency/productivity, and ultimately reduced 
costs and waste.1 In addition, adopting a standardized PN order format designed with ingredients 
listed in the same sequence may improve consistency, and clarifying orders decreases the risk of  
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Figure 2. Parenteral Nutrition Order Template: Pediatric/Neonatal Patient. !
errors when patients transition care from one setting to another. The Agency for Healthcare 
Research and Quality recently reported on a meaningful reduction in errors (from 9 to 2 per 1000 
PN orders) at a children’s hospital that adopted a standardized ordering and administration 
process for PN.6 Other observations included a reduced need for pharmacists to correct orders, a 
more efficient ordering and administration process, earlier delivery and administration, and an 
associated increase in staff satisfaction.6 !
The use of electronic or computerized PN orders can also improve efficiency and safety and 
reduce errors. Maat and colleagues demonstrated a significant 16% time reduction for simple and 
a 60% time reduction for complex calculations related to PN prescribing in neonates when using 
a CPOE system with basic clinical decision support.7 Brown and colleagues completed a 
retrospective cross-sectional study evaluating the impact of an interactive computerized PN 
worksheet on PN–prescribing errors. The worksheet was developed using commonly available 
spreadsheet software (ie, not part of an integrated CPOE system), but still required separate entry 
and transcription of the PN order. While use of the worksheet was associated with a reduction in 
the prescribing error rate, all of the errors that did occur were attributed to transcription or data 
entry mistakes.9 Shamliyan and colleagues completed a review of studies to examine the 
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association between computerization of physician orders and prescribing medication orders.8 
Computerized orders were associated with a 43% reduction in dosing errors, 37.5% reduction in 
adverse drug events, and 66% reduction in total prescribing errors in adults.8 Of the studies 
included in this review, 80% reported a significant reduction in total prescribing errors.8 While 
these data are not specific to PN therapy, they do highlight the benefits of CPOE on the 
medication use process and associated errors and adverse drug events. !
The ISMP reported a case of a 16-year-old boy who received a PN order in which the ingredients 
were ordered in amounts per kg, but the PN admixture was prepared in amounts per day.21 This 
resulted in infusion of a hypo-osmolar PN admixture (138 mOsm/L) with very low doses of 
nutrients (eg, protein and dextrose both at 1 g/d rather than 1 g/kg/d) for almost an entire day 
before it was identified (no adverse effects were incurred by the patient). There were multiple 
failures across the entire medication use process in this scenario. For example, the PN order 
template in the CPOE system did not match the template in the pharmacy system/Automated 
Compounding Device (ACD). Further, there was a lack of clinical decision support and 
automated warnings in both the CPOE PN order template and the ACD, a lack of redundancies in 
the process, and multiple points of transcription. ISMP provided several safe practice 
recommendations21: !
• Match prescribing and pharmacy templates 
• Build, test, and heed automated warnings 
• Heighten suspicions of errors 
• Carry out effective redundancies 
• Provide clear labeling (and the label should always match the PN order template in the PN 
order form/CPOE system and the ACD) 
• Educate and validate competency 
• Eliminate transcription of PN orders !
Despite the potential advantages of CPOE, use of CPOE with respect to PN orders appears to be 
limited. A 2011 survey of PN practices noted that a CPOE system was used for PN orders in only 
33% of the surveyed organizations.22 Most recently, Radley et al conducted a systematic review 
of the literature and derived a summary estimate of the effect of CPOE using a random effects 
meta-analytic technique. Their pooled analysis revealed that implementing CPOE was associated 
with a 48% (95% CI, 41%–55%) reduction in medication error rates. They further estimated that 
as many as 104 million medication errors could be averted annually if all hospitals fully adopted 
CPOE to process all medication orders.23 To the best of our knowledge, only one large 
commercial Health Information System–Electronic Medical Record/CPOE system provides even 
rudimentary PN calculation or decision support capability. !!!
Question: Prescribing 3 (P3) !
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(P3) What improvements in the physical environment would promote safe PN ordering and use? !
Recommendations !
Institutions shall meet the following requirements for the physical environment as described in 
The United States Pharmacopeial Convention, USP General Chapter <1066>: !
1. Illumination: USP <1066> recommends the following lighting levels for healthcare 
settings24:  
Computer order entry    1000 Lux 
Handwritten order processing   1000 Lux 
Sterile compounding and preparation  1000–1500 Lux 
Medication preparation area   1000 Lux 
Medication administration work area  1000 Lux 
2. Interruptions and distractions: The 2008 USP MEDMARX Data Reports noted distractions 
rank high (approximately 45%) as contributing to medication errors in hospitals and health 
systems.25 
3. Sound and noise: The standard for sound levels for medication safety zones is set at 50 
decibels A-weighted for sound (dBA), the level of conversation.24  
4. Physical design and organization of work space: The design of the workplace environment 
can influence the effectiveness of the prescriber to perform tasks.24 USP <1066> promotes 
ergonomic design of the workplace environment. Factors such as counter height, height of 
supplies, drawer lighting, and work clutter are noted to influence efficiency as well as safety.  
5. Medication safety zones: Defined as a critical area where medications are prescribed, orders 
are entered into a computer or transcribed onto paper documents, and where medications are 
prepared, dispensed, or administered.24  !
Rationale !
The process of ordering/prescribing PN is very complex and requires an environment that 
promotes safety. According to the United States Pharmacopeia (USP), the work environment has 
been identified as one of the most common reported factors known to contribute to medication 
errors.24 In October 2010, The United States Pharmacopeial Convention published an official 
bulletin titled Physical Environments That Promote Safe Medication Use, General Chapter 
<1066>. This chapter focuses on the characteristics of the physical environment that are 
essential to promoting accurate medication use.24 These guidelines provide an excellent resource 
to promote safe prescribing for the nutrition support clinicians to incorporate into their practice. !
Question: Prescribing 4 (P4) !
(P4) How often should the PN prescription be reordered after the initial order? !
Recommendations 
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!
1. An institution-specific or organization-specific policy should be created to dictate the 
duration of a PN order. 
2. When reordering PN, each PN component should be reordered in its entirety, including full 
generic names and doses. 
3. Patients with newly initiated PN should be monitored and have their orders reviewed more 
frequently. 
4. The reordering process should be structured to require accountability for reviewing the 
orders, laboratory findings, and patient’s condition. Simple processes (eg, a single-step 
“renew order” button) that lack this accountability should not be used. The following are 
categories for patients and examples for their corresponding monitoring frequencies:  
a. Patients who are new to PN should be monitored daily until stable (more frequently if 
clinically significant metabolic abnormalities are found or patient is at risk for refeeding 
syndrome).  
b. Patients in an unstable clinical condition (eg, acutely ill, critically ill, recovering from 
critical illness, recent surgery) should be monitored daily until stable (more frequently if 
clinically significant abnormalities are observed).  
c. Stable patients in the hospital with no required changes in formulation for 1 week should 
be monitored every 2 to 7 days. 
d. Stable patients in a hospital, long-term care, or home setting with no changes in 
formulation for more than 1 week should be monitored every 1 to 4 weeks or longer in 
select clinically stable patients. !
Rationale !
There are no known studies that examine whether the duration of a PN order or the frequency 
with which such orders are renewed impacts outcomes or safety measures. However, the 
collaborative multidisciplinary care approach and application of safe practices guidelines have 
repeatedly proven to reduce complications, costs, and inappropriate use of PN.26 It is reasonable 
to assume that patients newly initiated on PN, especially those with preexisting electrolyte 
abnormalities or at risk for refeeding syndrome or with unstable clinical status (such as those 
newly critically ill or postoperative patients), will require more frequent monitoring. Similarly, 
patients who have been stable for some time may need less frequent monitoring. Policies 
regarding the frequency of PN order renewals improve monitoring practices. Protocols for 
ordering PN may be designed such that laboratory values must be entered or acknowledged prior 
to submitting the order as is common in home infusion practice. Published guidelines and 
literature on prescribing should be adopted and reinforced and each healthcare organization shall 
include clinicians with expertise in the area of nutrition support, preferably from multiple 
disciplines in the prescribing process.5,6 !!
Question: Prescribing 5 (P5) !
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(P5) How can education be provided to non-nutrition support specialist clinicians to improve PN 
prescribing and safety? !
Recommendations !
1. Prescribers from all disciplines, including physicians, pharmacists, nurse practitioners, 
physician assistants, and dietitians, should be educated on basic PN prescribing and 
monitoring. 
2. Introductory didactic and experiential education/training about PN should be included in the 
core curriculum. Knowledge and skills should be evaluated for all clinicians in each 
discipline involved with PN as determined by the individual institution. Education and 
assessment materials and processes shall be developed and led by clinicians with expertise in 
the area of nutrition support, preferably from multiple disciplines.5,6  
3. In-depth education on PN should be included as a standard component of acute care and 
home care pharmacy and physician residency training. This is also applicable to all 
pharmacists, nurses, dietitians, physicians, physician extenders, and other clinicians involved 
in caring for patients who receive PN. !
Rationale !
There are few known studies evaluating the impact of safe prescribing education programs on the 
outcomes of patients receiving PN. Interdisciplinary teams, applying education as part of an 
overall quality intervention, have been successful in reducing unnecessary PN use and 
decreasing errors.20 In general, participating in PN education programs has been associated with 
improvement in safer prescribing practices.27 Such programs are well received by students who 
perceive a large gap in their training in safe prescribing practices.28-30 Safe prescribing, both in 
general and specific to PN, should be a component of all clinical training, including the core 
curricula of professional programs (medical, pharmacy, advanced practice nurse prescribers, 
nursing, nutrition, physician assistant, etc), residency, and specialty/fellowship programs for all 
who may be engaged in prescribing PN. !
Topics for Further Research !
1. Documentation of errors associated with PN prescribing 
2. Impact of PN template standardization on PN prescribing and transcription errors 
a. Impact of listing PN ingredients in the same format using amounts per day (or amounts 
per kg/d), using standard units of measure (eg, mEq, mmol) on PN ordering and 
transcription errors, especially with transition or transfer of patient care  
b. Impact of listing PN ingredients in a standard sequence on PN order forms and whether 
this can improve communication and reduce PN transcription-related errors, especially 
with transition or transfer of patient care  
3. Impact of electronic PN orders and use of clinical decision support on accuracy and safety of 
PN therapy 
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a. Impact of electronic orders and clinical decision support vs handwritten paper PN orders 
on PN prescribing error occurrence 
b. Impact of CPOE interface with ACDs vs no interface vs handwritten or verbal 
transcription/communication on PN prescribing and transcription errors  
4. Demonstration of improved patient outcomes with incorporation of appropriate monitoring 
parameters on the PN prescription 
5. Impact of a standard commercial PN product (premixed) vs compounded PN formulation on 
prescribing errors 
6. Demonstration of improvement in time to achieve nutrition goals and reduced length of stay 
with consultation from a nutrition support clinician during the PN ordering process  
7. Impact of healthcare organization PN education programs, PN competency assessment, and 
credentialing/certification on PN ordering errors and PN safety  
8. Impact of PN clinical effectiveness or quality improvement processes on PN prescribing 
errors !
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Parenteral Nutrition Order Review and Verification Process !
Background !
PN is a highly complicated therapy administered to patients in hospitals and alternative sites 
including the home and long-term care facilities. PN formulations may contain more than 40 
ingredients, including amino acids, dextrose, IVFE, electrolytes, vitamins, trace elements, 
insulin, and other medications. PN is considered a high-alert medication because significant 
patient harm may occur when this therapy is used in error.1,2 A critical step in the PN process is a 
pharmacist’s review and verification of PN orders. Breaches in the review and verification 
processes have resulted in errors and patient harm.1 Healthcare organizations have the 
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opportunity to improve the safety of PN therapy by optimizing technology for prescribing PN 
and transmitting PN order information as well as standardizing the PN review and verification 
processes. !
Question: Verification 1 (V1) !
(V1) What are the essential components or attributes for safely transmitting PN orders to 
pharmacists for review and verification? !
Recommendations !
1. PN should be prescribed using a CPOE system that is fully integrated with an automated 
compounding device (ACD).3 “Fully integrated” is described to mean that the order entered 
into the CPOE system is transmitted electronically to the ACD without requiring reentry of 
any data and any modifications to an order are electronically transmitted back to the CPOE 
system for physician approval and signature.  
2. When PN formulations are outsourced to a third-party vendor for compounding, PN orders 
should be prescribed using a CPOE system and electronically transmitted to the vendor to 
avoid transcription errors.  
3. In the absence of a fully integrated system, PN should be prescribed using a standardized 
order template as an editable electronic document in order to avoid handwritten orders. 
4. Verbal and telephone orders for PN should be avoided except for pharmacist to prescriber 
communication to modify or clarify the order.  
5. PN order data should be in a standardized format, including standardized sequence of 
ingredients, standard units, standard formulas, and formulation options1 as described above 
in the Questions (P1–P2).  
6. If transcription into the ACD is required, the output of the PN order data should be formatted 
to support direct entry into the ACD without requiring reordering of the ingredients, manual 
calculations of amounts, or unit-of-measure conversions.  
7. Data should only be manually transcribed from the PN order into the ACD when absolutely 
necessary. Transcribed data should always be double-checked by independent processes to 
monitor accuracy.4 Multiple manual transcriptions of PN order data should be avoided.  
8. PN orders should be prescribed, transmitted, and compounded when supported by properly 
trained personnel who regularly perform this task.5 This is usually during the daytime hours. 
9. Vendors and application architects for CPOE systems should place priority on developing 
pathways for prescribing PN that support the prescriber with appropriate clinical decision 
support (as previously described), enforce standards of practice, and communicate directly 
with ACDs.  
10. Application vendors and application architects for CPOE systems should collaborate with 
ACD manufacturers to develop fully integrated systems.  
11. Application vendors and application architects for CPOE systems should collaborate with 
ACD manufacturers and outsourcing pharmacies to develop fully integrated systems. !
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Rationale !
Few healthcare organizations currently use a CPOE system for prescribing PN formulations that 
is fully integrated with an ACD. While some healthcare organizations use a CPOE system for 
prescribing PN, the majority continue to use paper order forms to prescribe PN, including 
handwritten orders.6-8 Outsourcing pharmacies receive PN data in a variety of formats, including 
handwritten forms, which are commonly transmitted to the pharmacy. This may necessitate unit-
of-measure conversion calculations, data manipulation, and transcription, which may result in 
errors. Editable electronic documents allow prescribers to complete orders and avoid the risks 
associated with handwritten orders.9,10 The lack of integration of the PN order with an ACD 
requires the manual entry of PN order data, which may lead to transcription errors.11 A recent 
survey of PN practices reported that more than half of PN orders are transcribed by a pharmacist 
from handwritten orders or a printed label or requisition.8 Two recent reports from the ISMP 
describe transcription errors. One was the death of a 6-week-old infant who received a dose of 
sodium 60 times the prescribed amount.12 The second report describes a PN order data entry 
error in which nutrients were entered into an incorrect PN template, resulting in a patient 
receiving a hypotonic PN formulation.3 Sacks et al also described a PN system in which PN 
order data were transcribed from a handwritten order into a hospital pharmacy computer and then 
reentered into the ACD, thereby increasing the risk for transcription errors.11 If the PN process 
requires transcriptions, limiting the number of times data are entered from one system to another 
will decrease the risk of data entry errors. PN errors associated with incorrect calculations or 
converting units of measure have been reported and may result in patient harm. The ISMP 
reported the death of a neonate who received PN that included zinc at a dose 1000 times the 
prescribed amount. This error was the result of a calculation error in converting mcg/100 mL to 
mcg/kg/d.5 !
There are numerous CPOE vendors but few offer templates for prescribing PN that are user-
friendly, allow institution-specific customization, or interface with an ACD. Although the 
number of orders for PN is a small percentage of the total number of medications prescribed, it is 
one of the most complex and complicated therapies provided by pharmacies. A CPOE system 
that is fully integrated with an ACD improves the safety of the PN process.3 !
Question: Verification 2 (V2) !
(V2) What improvements in the PN review and verification processes will enhance the safety of 
PN therapy? !!!!
Recommendations !
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1. Healthcare organizations shall have a written policy and procedure for pharmacists to review 
and verify PN orders. 
2. The review and verification of PN orders should be conducted in an environment without 
distractions. 
3. PN orders shall be reviewed by a knowledgeable and skilled pharmacist to assess that the 
order is clear and complete. 
4. The PN order shall include the following elements: 
a. Complete patient identifiers (patient name, medical record number or other unique 
identifiers, patient location) 
b. Birth date and/or age 
c. Allergies and associated reactions 
d. Height and dosing weight in metric units 
e. Diagnosis/diagnoses 
f. Indication(s) for PN 
g. Administration route/vascular access device (peripheral vs central) 
h. Contact information for prescriber 
i. Date and time order submitted 
j. Administration date and time 
k. Volume and infusion rate 
l. Infusion schedule (continuous or cyclic) 
m. Type of formulation (dextrose/amino acids with separate infusion of IVFE or total 
nutrient admixture) 
n. All PN ingredients shall be ordered as follows: 
1. Ingredients ordered as amounts per day (for adult patients) or amounts per kilogram 
per day (for pediatric and neonatal patients) rather than in amounts per liter, percent 
concentration, or volume.1 “Amount per day” refers to macronutrients in grams per 
day and micronutrients in mEq, mmol, mcg, or mg per day. 
2. Electrolytes shall be ordered as the complete salt form rather than the individual ion. 
3. The PN order should contain the full generic name for each ingredient.1,13 Brand 
names should only be used when multiple products exist and/or when the brand name 
may assist in identifying unique properties of the specific dosage form (eg, inherent 
electrolytes in amino acid formulations, fatty acids in IVFE).1,13 
4. All abbreviations shall follow The Joint Commission standards on abbreviations.13,14 
Abbreviations on the ISMP’s list of error-prone abbreviations, symbols, and dose 
designations shall not be used.15  
o. A dose for each macronutrient 
p. A dose for each electrolyte 
q. A dose for vitamins, including multivitamins and/or individual vitamin entities. 
Multivitamins shall be included daily in PN formulations1,16  
r. A dose for trace elements, including multicomponents and/or individual trace element 
entities 
s. A dose for each non-nutrient medication (eg, insulin) 
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5. PN orders shall undergo a clinical review to assess appropriateness and shall include the 
following elements: 
a. Indication is consistent with published guidelines. 
b. Calculated osmolarity of the PN formulation is appropriate for the route of 
administration/vascular access device (peripheral vs central).1  
c. Each additive macronutrient, micronutrient, non-nutrient medication (eg, insulin) is 
evaluated to confirm that the dose is clinically appropriate for the patient’s nutrition 
needs, metabolic status, organ function, allergies, concomitant interventions, and other 
indices, and to confirm that the dose is consistent with institutional practice standards.  
d. The formulation is compared with the previous day’s PN formulation, if any, to assess for 
substantial additions, deletions, increases, or decreases in dosages of macronutrients, 
micronutrients, or medications (eg, insulin).  
e. When laboratory data are available, updated laboratory values that have been reported 
since the order was submitted should be reviewed for significant changes and, if present, 
the appropriateness of additive dosing should be reevaluated.  
6. PN orders shall undergo a formulation safety review that includes the following elements: 
a. All ingredients are evaluated for compatibility with each other. Calcium-phosphate 
precipitation risk should be assessed according to institutional policies and procedures.  
b. PN formulation is evaluated for expected stability from the time of preparation until the 
time that administration of the PN is complete. For example, emulsion stability of a total 
nutrient admixture should be evaluated.  
7. Healthcare organizations shall develop policies and/or protocols to clarify PN orders when 
doses are outside normal ranges or potential incompatibilities may exist (eg, adjusting 
calcium and phosphate doses to avoid the risk of calcium-phosphate precipitation, adjusting 
the IVFE dose when it is not expected to be stable as a TNA [ordering IVFE separately or 
adjusting IVFE dosage such that the daily dose achieves minimum concentration for 
stability]). 
8. Modifications to the prescriber’s original PN order shall be communicated to the licensed 
prescriber (or their designee) and documented in the patient’s medical record in a manner 
that is auditable.  
9. All PN orders that require transcription of order data should undergo an independent double-
check4 process prior to compounding the PN formulation. The double-check shall be 
documented and auditable.  
10. All PN orders requiring calculations or conversion of units of measure should undergo an 
independent double-check4 process prior to compounding the PN formulation. All double-
checks shall be documented and auditable.  
11. Recommendations for pharmacy review of PN orders apply whether the pharmacist 
reviewing the PN order is on site or at a remote location from the prescriber. The time 
dedicated for the pharmacist(s) to review PN orders should be based on the average number 
of PN orders and the estimated time to review, clarify, and/or modify a PN order at an 
organization.  
12. PN orders that are completed in a hospital but outsourced to a third-party pharmacy for 
compounding and PN orders submitted to home infusion pharmacies should undergo the 
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same standardized pharmacy review and verification process prior to transmission to the 
pharmacy for compounding.  
13. Institutions shall create a home PN order process that provides a safe plan for multiple days 
of therapy. The prescription for home PN therapy should be written in a format that 
specifically reflects trends in laboratory values and previous days of PN therapy. An 
institutional daily PN order format should not be used as a home PN prescription.  
14. Pharmacies have the same responsibility of maintaining the PN orders in their records as 
with other medication orders. 
15. The healthcare organization shall develop criteria to evaluate and identify pharmacists who 
are competent to review and verify PN orders.  
a. Pharmacists responsible for the review and verification of PN orders should have 
completed specialty residency training and/or be certified as a Board Certified Nutrition 
Support Pharmacist (BCNSP) by the Board of Pharmacy Specialties (BPS).  
b. In the absence of pharmacists with specialty residency training or BCNSP certification, 
the organization should have methods to identify and evaluate pharmacists competent to 
review and verify PN orders such as the certification program offered by the National 
Board of Nutrition Support Certification (NBNSC) until such time that a pharmacist with 
specialty residency training or BCNSP certification is available.  
c. In the absence of pharmacists with specialty residency training or BCNSP certification, 
the organization should provide formal training programs or an opportunity to participate 
in formal training programs to increase knowledge and skills in nutrition support and 
with a goal of becoming certified in nutrition support. Training should focus on 
evaluating dosage of macronutrients and micronutrients as well as prescribing non-
nutrient medications (eg, insulin) and their compatibilities and stabilities in PN. 
16. Pharmacists who review and verify PN orders should demonstrate competency at least 
annually. 
17. Quality improvement programs should be in place to report, track, and analyze errors 
associated with the PN order review and verification process. !
Rationale !
The review of medication orders, including PN orders, involves many steps in which the 
pharmacist evaluates the order for safety, efficacy, and appropriateness. These processes require 
knowledge of PN therapy and formulations; critical thinking and decision making by the 
pharmacist is crucial, and appropriate allotment of time is necessary.2,17 Before any PN 
formulation is compounded, the PN order is reviewed and verified. Standardizing these processes 
satisfies that all elements are included and the order is complete. The review and verification of 
PN orders includes both a clinical review and a pharmaceutical review. The verification is 
conducted to check that the PN order is complete and that the appropriate vascular access is in 
place for new patients beginning PN.2 Additionally, the clinical review evaluates the 
appropriateness of the dose of each macronutrient and micronutrient as well as non-nutrient 
medications in the PN formulation. A pharmaceutical review of PN orders is also conducted to 
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determine if the prescribed components are compatible and if the PN formulation is expected to 
be stable.2 !
A recent survey of PN practices reported that most institutions (60.2%) dedicate 0.6 full-time 
equivalent or more pharmacists to verify and review PN orders. However, 23.1% did not have 
any dedicated pharmacist time for these tasks. When a pharmacist is involved, most conduct both 
a clinical and pharmaceutical review of PN orders. The 2012 survey by the American Society of 
Health-System Pharmacists of pharmacy practice in hospitals reports that 11.1% of hospital 
pharmacies have pharmacists responsible for monitoring patients receiving PN therapy.18 !
The complexity of PN orders necessitates special knowledge and skills to adequately review PN 
orders. Special training programs focusing on all aspects of the review process, especially the 
total daily dose of PN components, will improve the review process and heighten the 
pharmacist’s awareness and ability to identify errors.12 Identification of errors in turn requires 
follow-up and/or clarification with the prescriber. In the recent survey of PN practices conducted 
by Boullata et al, the reasons for PN order clarification included illegible orders, doses outside 
normal ranges, incompatible additives, and incorrect PN volume or infusion rate.8 Errors and 
patient harm have also occurred when pharmacists misinterpreted information on the PN label 
when patients transferred from one healthcare setting to another (eg, home to hospital).1 Failure 
to follow and be judicious with the verification and review processes have resulted in adverse 
events.1,3,5,12 Certification in nutrition support validates an individual’s qualifications and level of 
knowledge to practice in this area.19 BPS criteria for recognition states that the area of 
specialization shall be one for which specifically trained practitioners are needed to fulfill the 
responsibilities of the pharmacy profession in improving the health and welfare of the public, 
which are responsibilities that may not otherwise be fulfilled effectively. Nutrition support 
pharmacy practice fulfills that criteria.19 In one paper, staff obtained certification in nutrition 
support and targeted individuals with specialty certification when recruiting for new staff. This 
resulted in a substantial increase in knowledge and ability of pharmacists to manage the 
associated complexities of PN.20 !
Question: Verification 3 (V3) !
(V3) What are the steps healthcare organizations can take to improve the PN label and labeling 
system? !
Recommendations !
1. Healthcare organizations shall have a policy and procedure/protocol for standardized 
labeling of PN formulations. 
2. Elements of the PN label include1: (see Figure 3 and Figure 4) 
a. Two patient identifiers (eg, name, medical record number, date of birth) 
b. Patient location or address 
c. Dosing weight in metric units 
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d. Administration date and time 
e. Beyond-use date and time 
f. Route of administration (central vs peripheral vascular access) 
g. Prescribed volume and overfill volume 
h. Infusion rate expressed in mL/h 
i. Duration of the infusion (continuous vs cyclic) 
j. Size of in-line filter (1.2 or 0.22 micron) 
k. Complete name of all ingredients 
l. Barcode 
m. All ingredients shall be listed in the same sequence and same units of measure as PN 
order. 
• All PN ingredients shall be ordered in amounts per day (for adult patients) or amounts 
per kilogram per day (for pediatric and neonatal patients) rather than in amounts per 
liter, percent concentration, or volume. “Amount per day” refers to macronutrients in 
grams per day and micronutrients in mEq, mmol, mcg, or mg per day. 
• Electrolytes shall be ordered as the complete salt form rather than the individual ion. 
Each individual macronutrient and micronutrient ordered shall be listed with its 
corresponding dose. 
• For home or alternative site PN labels, a list of patient/caregiver additives shall be 
included; these additives shall be easily identified and differentiated from the other 
PN components. Techniques to identify patient additives include highlighting or an 
asterisk to identify the additives that are added just prior to administration.  
3. Name of institution or pharmacy 
4. Institution or pharmacy contact information, including telephone number 
5. Auxiliary labels may be used to express individual electrolytes as mEq and the phosphorus 
content as mmol per day. The label may also include information on the amount of energy 
provided by each macronutrient or electrolytes intrinsic to the amino acids product. 
6. If IVFEs are infused separately (vs TNA), the essential elements of the IVFE label are: (see 
Figure 5 and Figure 6) 
a. Two patient identifiers (name, medical record number, date of birth) 
b. Patient location or address 
c. Dosing weight 
d. Administration date and time 
e. Route of administration (central vs peripheral access) 
f. Prescribed amount of IVFE and volume required to deliver that amount 
g. Infusion rate expressed in mL/h 
h. Duration of the infusion (not longer than 12 hours) 
i. Complete name of the IVFE, even though label placed on original manufacturer 
container 
j. Beyond-use date and time 
k. Name of institution or pharmacy 
l. Institution or pharmacy telephone number 
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7. Labels for home PN formulations should be consistent with USP General Chapter <17>.21 
(See Figure 7) 
a. Organize the prescription label in a patient-centered manner. 
• Organized in a manner that best reflects how most patients seek out and understand 
medical information 
• Includes only the most important patient information needed for safe and effective 
understanding 
b. Emphasize instructions and other information important to the patient. 
• Prominently display information that is critical for patient’s safe and effective use of 
therapy 
• At the top of the label, specify the patient’s name, drug name (spelling out full 
generic and brand name), and strength/dose. Include explicitly clear directions for use 
in simple language 
• Directions should follow a standard format so the patient can expect that each 
element will be in the same regimented order each time the medication is received 
c. Simplify language 
• Language on the label should be clear, simplified, concise, and familiar, and should 
be used in a standardized manner. Only common terms and sentences should be used. 
• Use simplified, standardized sentences that have been developed to promote ease of 
understanding the instructions correctly. 
d. Give explicit instructions 
• Do not use alphabetic characters for numbers. 
• Use standardized directions. 
• List which PN ingredients must be added by the patient/caregiver. 
• Ambiguous directions such as “take as directed” should be avoided unless clear and 
unambiguous supplemental instructions and counseling are provided. 
e. Include purpose for use of PN using clear, simple terms such as “for nutrition 
supplementation” or “to provide nutrition” 
f. Limit auxiliary information 
• Auxiliary information should be evidence based in simple explicit language that is 
minimized to avoid distracting patients with nonessential information. 
• Information should be presented in a standardized manner and critical for patient 
understanding and safe medication use. 
• Use only icons for which adequate evidence suggests improved patient understanding 
about correct use of medication. 
g. Address limited English proficiency 
• Whenever possible, the directions for use should be provided in the patient’s 
preferred language, otherwise there is risk of misinterpretation of instructions with 
limited English proficiency, which could lead to medication errors. 
• Whenever possible, the directions for use should also appear in English to facilitate 
counseling. 
• Medication names shall be in English so that emergency personnel and other 
intermediaries can have quick access to the information. 
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• Translations of prescription labels should be produced using a high-quality translation 
process. 
h. Improve readability 
• Labels should be designed and formatted so that they are easy to read. 
• Optimize typography using: 
• high-contrast print 
• simple uncondensed familiar fonts with space within letters and between letters 
• sentence case with initial capital followed by lowercase words 
• large font size for critical information 
• adequate white space between lines of text 
• white space to distinguish sections on the label such as directions for use vs 
pharmacy information 
• horizontal text only 
• never truncate or abbreviate critical information 
• highlighting, bolding, and other typographical cues should preserve readability 
and should emphasize patient-centric information or information that facilitates 
adherence  
• limit the number of colors used for highlighting 
• address visual impairment !
Rationale !
PN formulations are complex mixtures with multiple ingredients. The pharmacy-generated label 
is a critical tool used to compare the PN ingredients and administration information against the 
PN order. Standardized pharmacy labels for PN formulations provide information in a clear, 
uniform, and organized manner, and improves the verification processes for pharmacists.1 
Additionally, the label serves as a final check for those administering the PN, including nurses or 
patients/caregivers.12,13 Listing ingredients in a uniform sequence and units of measure removes 
the need for calculations and reduces the risk of misinterpretation. The misinterpretation of a PN 
label resulted in a child receiving an overdose of iron dextran and experiencing subsequent liver 
toxicity from iron overload.22 The lack of standardization has created confusion, especially when 
patients are transferred from one healthcare environment to another.23 !
Question: Verification 4 (V4) !
(V4) What processes can healthcare organizations implement to improve the safety of PN 
therapy during shortages of PN components? !
Recommendations !
1. Healthcare organizations (including vendors and home infusion providers) shall have a 
process to communicate PN component shortages and outages to prescribers and staff who 
participate in providing PN therapy.24 
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Figure 3. Parenteral Nutrition Label Template: Adult Patient. 
*Specify product name. !
2. Healthcare organizations shall develop and approve written PN component substitution 
protocols to be used in the event of a PN component shortage or outage.24  
3. Healthcare organizations shall develop and approve written protocols for PN component 
substitution and/or conservation strategies to be used in the event of a PN component 
shortage or outage.24  
4. Healthcare organizations have a process to communicate PN component substitution 
protocols and PN component conservation strategies to prescribers and staff who participate 
in providing PN therapy.24 !
5. Healthcare organizations have a process to implement PN component substitution protocols 
and/or PN component conservation strategies to prescribers and staff who participate in 
providing PN therapy.24 
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Figure 4. Parenteral Nutrition Label Template: Pediatric/Neonatal Patient. 
aSpecify product name. 
bSince the admixture usually contains multiple sources of sodium, potassium, chloride, acetate, and phosphorus, the 
amount of each electrolyte/kg provided by the PN admixture is determined by adding the amount of electrolyte 
provided by each salt. !
6. PN component conservation and allocation strategies should include the A.S.P.E.N. PN 
product shortage considerations for multivitamins, trace elements, IVFE, amino acids, 
electrolyte/minerals, and cysteine. Thiamine, ascorbic acid, pyridoxine, and folic acid should 
be given daily. Thiamine is critical. Several deaths have resulted from cardiac failure due to 
thiamine deficiency when long-term PN patients did not receive vitamins for 3 to 4 weeks. 
Patients receiving a carbohydrate load are particularly susceptible to thiamine deficiency.
16,25-29 !
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Figure 5. Standard Intravenous Fat Emulsion Label Template: Adult. 
aSpecify product name. !
7. Processes shall be in place to evaluate alternative PN components procured from 
compounding pharmacies, including compliance with USP General Chapter <797> 
Pharmaceutical Compounding-Sterile Preparations, federal laws and regulations, and state 
Boards of Pharmacy rules and regulations.  
8. Processes should be in place to modify the PN order to reflect component outages and/or 
conservation strategies in a timely manner. 
9. Processes should be in place to modify the PN label to reflect changes in the PN order due to 
component outages and/or PN component conservation strategies.  
10. Processes should be in place to modify ACD software to reflect changes in PN components 
due to outages and/or conservation strategies. This includes compatibility of all ingredients 
and changing National Drug Code (NDC) numbers, which is mandatory for barcoding 
systems to function correctly. Any changes in ACD software should require two individuals 
to perform the validation check using a standardized process and checklist. 
11. Quality improvement programs should be in place to track and analyze errors associated with 
PN component outages and shortages. Errors associated with outages and shortages should 
be reported to the ISMP National Medication Errors Reporting Program. !
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!
Figure 6. Standard Intravenous Fat Emulsions Label Template: Neonate or Pediatric Patient. 
aSpecify product name. !
12. Severe PN component shortage information should be reported to the FDA Drug Shortage 
Program, ASHP, and A.S.P.E.N. 
13. During outage or shortage of PN components, clinicians shall monitor patients for 
deficiencies. Anticipate an increase in deficiencies with ongoing shortages. Increase 
awareness and assessment for signs and symptoms of electrolyte and mineral deficiencies. 
14. Providers may need to seek out other sources of PN components by coordinating with other 
healthcare institutions or other infusion companies. !
Rationale !
The drug shortage crisis continues in the United States and threatens the integrity of the 
pharmaceutical supply chain and compromises patient care, especially patients requiring PN 
therapy.30 The number of new drug shortages has increased over the past 5 years, with the most 
significant being sterile injectable products. !
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To assess the effect of drug shortages on patient safety, the ISMP surveyed healthcare 
professionals. More than 1800 healthcare professionals responded and reported 1000 medication 
errors or adverse patient events due to a drug shortage. Of those who responded, 35% reported 
their institution had experienced a near miss during the past year due to a drug shortage; 25% 
reported an actual error, and 20% reported an adverse patient outcome.31 Another drug shortage 
survey was conducted by Premier Healthcare Alliance. Over 300 pharmacy experts from 
hospitals and other healthcare sites participated. Shortages that may have resulted in a 
medication safety issue or error in patient care were reported as having been experienced by 89% 
of respondents.32 !
To understand the impact of PN product shortages on patient safety, each step of the PN process 
should be considered. The steps of the PN process include procurement, management, 
prescribing, order review, compounding and dispensing, administration, monitoring, and patient 
outcomes. In a recent survey, 16.4% of respondents reported that patient outcome was directly 
affected by PN-related product shortages, including nutrient deficits, increased length of stay, 
and increased morbidity and mortality.8 Managing PN product shortages includes activities such 
as developing and revising policies and procedures for rationing or restricting PN products, use 
of alternative products, prescribing systems, and changes in compounding and dispensing as the 
result of shortages. !
PN product shortages may be so critical that prescribers may elect not to provide PN therapy 
because there are no products to prevent or treat complications. Outsourcing pharmacies may 
dictate to customers PN product conservation strategies. Although this is severe, the PN product 
shortages have resulted in prescribing suboptimal therapy due to shortages or rationing of 
products. The prescribing step is affected as prescribers find it difficult to keep up with 
shortages, alternative products, rationing, restrictions, and so on. Furthermore, the prescribing 
process is constantly changing, and prescribers may use workarounds to circumvent safety 
checks. Lastly, an increase in the number of prescribing errors has been associated with 
shortages.30,31 !
Many of the same safety concerns have been identified in the PN order review step. Pharmacists 
who perform this step have difficulty staying current with shortages, alternative products, and 
rationing. There has been an increase in the number of PN orders that require clarification or 
those with prescribing errors. !
The compounding and dispensing steps are associated with numerous patient safety issues 
resulting from PN product shortages. As with other aspects of the PN process, those responsible 
for compounding and dispensing find it difficult and stressful trying to keep up with the many 
shortages. During a shortage, alternative products that are unfamiliar or are similar in appearance 
to other products may be substituted. This may lead to errors. Furthermore, PN may be 
compounded using alternative products such as calcium chloride or magnesium chloride, for 
which there are insufficient stability and compatibility data or known unfavorable differences. 
Frequent changes in PN products or the size of the source containers necessitate a change in the 
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configuration of ACD, increasing the potential for error. Some products cannot be configured for 
the ACD, requiring a manual addition to a PN formulation. Frequent changes in products, 
alternative products, ordering process, and ACD configuration may result in PN orders and PN 
bag labels that do not match. This creates significant concerns for those responsible for the 
administration of the PN admixture. !
The PN product shortages affect the administration of PN whether administered by a nurse, 
patient, or caregiver. Just like others involved in the PN process, it is difficult and stressful to 
keep current with the shortages. As noted above, the PN order and PN bag labels may not match 
as the result of changes in the compounding process. With some shortages, patients may require 
supplemental electrolyte or mineral infusions when the alternative product cannot be added to 
the PN formulation due to stability or compatibility concerns. Increasing the number of times the 
patient’s intravascular device is accessed may increase the risk of catheter-related bloodstream 
infections.30 A recent study of PN practices reported the consequences of PN product shortages. 
Of the pharmacists responding, more than two-thirds reported that valuable time is consumed in 
developing contingencies. Additionally, 70.3% of respondents indicated that shortages interfere 
with the ability to meet patients’ micronutrient needs, and almost half reported that shortages 
interfere with ability to meet macronutrient needs.8 !
The lack of a PN component increases the risk of a deficiency of that nutrient or complications. 
Shortages have been associated with patient harm. Anemia and leukopenia due to copper 
deficiency has been reported in an adult patient receiving PN without trace elements for 4 
months.33 Clinicians must have a heightened awareness of potential deficiencies and monitor for 
the deficiencies or associated complications. !
The shortages pose safety risks throughout the entire PN process, from procurement to patient 
outcomes. Providing PN therapy during product shortages requires vigilance and continuous 
assessment of the entire PN process to optimize patient care quality and avoid patient harm. !
Topics for Future Research !
1. Demonstration of decrease in PN errors when CPOE systems are fully integrated with ACDs. 
2. Demonstration of decrease in PN errors with elimination of handwritten paper PN orders and 
use of editable electronic orders or CPOE systems for prescribing PN. 
3. Documentation of PN errors associated with PN verification process. 
4. Documentation of PN errors associated with the clinical and pharmaceutical reviews of PN 
orders. 
5. Documentation of PN errors associated with transcription of PN data from the order to an 
ACD. 
6. Impact of PN order standardization on PN data transcription errors. 
7. Demonstration of PN error reduction with implementation of standardized review and 
verification of PN orders. 
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8. Demonstration of a reduction in PN errors with implementation of a standardized checklist 
for the verification and review of PN orders. 
9. Impact of a fully integrated electronic system for prescribing PN and data into an ACD. 
a. Demonstration of medication error reduction 
b. Demonstration of improved patient safety 
c. Demonstration of decreased costs 
10. Documentation of PN errors associated with PN order calculations. 
11. Documentation of PN errors associated with misinterpretation of PN bag labeling. 
12. Demonstration of PN error reduction with standardized PN labeling. 
13. Development and implementation of a standardized home PN label that is consistent with the 
A.S.P.E.N. Safe Practices for PN and USP General Chapter <17>.  
14. Evaluation of patient understanding and satisfaction with PN labeling that is consistent with 
the A.S.P.E.N. Safe Practices for PN and USP General Chapter <17>. 
15. Demonstration of reduction in PN errors when PN orders are reviewed by a pharmacist with 
specialty residency training and/or BCNSP certification. 
16. Report of successful PN formal training programs for pharmacists and pharmacy technicians. 
17. Demonstration of PN error reduction with PN formal training programs for pharmacists and 
pharmacy technicians. 
18. Compatibility of PN components, including macronutrients, micronutrients, and non-nutrient 
medications. 
19. Determination of maximum osmolarity of PN formulations for administration via peripheral 
veins. 
20. Impact of PN product shortages on patient outcomes. !
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Compounding !
Background !
Recent PN errors caused by a knowledge deficit, lack of training, insufficient competency, and 
poor proficiency with ACDs are areas of significant concern. Additionally, a lack of competency-
based educational curriculum in schools of pharmacy or pharmacy technician training programs 
may contribute to PN errors. Very few suitable studies exist that characterize the formalized 
training of pharmacy students or technicians in the preparation of sterile products and 
admixtures. Available data suggest that when pharmacy students are formally taught aseptic 
technique skills with direct observation and assessment of parenteral compounding procedures, 
microbial contamination rates related to medium-risk level compounding (eg, PN compounding) 
decreased significantly from baseline toward the end of the 16-week course.1 Several 
recommendations pertaining to the knowledge and competency of staff involved in the 
preparation of compounded sterile products were developed at the recent ISMP Sterile 
Preparation Compounding Safety Summit.2 Surveys of pharmacists at the beginning of 
postgraduate training programs demonstrated that first-year pharmacy residents reported minimal 
experience (median = 2) on a scale from 1 to 5 (5, most experience and 1, no experience) with 
PN evaluations and IV admixtures. This suggests that there are educational deficits in current 
pharmacist training related to areas important for institutional or homecare pharmacy practice.3 
Observational data from practicing hospital pharmacists and pharmacy technicians revealed that 
compounding error rates were 37% when PN formulations were manually compounded and 22% 
when prepared with an ACD. Errors included touch contamination, incorrect calculations 
performed by technicians, and bypassing the built-in safety check systems on ACDs.4 !
Question: Compounding 1–2 (C1–C2) !
(C1) What compounding errors have been caused by deficits in knowledge, lack of training, 
competency, and proficiency? !
(C2) What compounding errors have been caused by a lack of standardized educational 
curriculum in schools of pharmacy or pharmacy technician programs? !
Recommendations !
1. Schools of pharmacy in the United States shall develop curricula that address proper aseptic 
technique and USP Chapter <797> for making compounded sterile preparations (CSPs). 
2. Pharmacy technicians shall be certified by the Pharmacy Technician Certification Board if 
they are involved in the making of CSPs, including PN. 
3. Healthcare organizations shall provide a broad orientation with an in-depth training program 
focusing on CSPs for all staff members supervising or participating in the preparation 
process. An ongoing competency assessment program shall be included in the training as 
well. 
!35
4. Healthcare organizations shall require annual competency evaluations of pharmacists and 
pharmacy technicians involved in preparation of CSPs. This should include: 
a. Calculations 
b. Compounding base solutions 
c. Preparing dilutions or aliquots 
d. Aseptic technique manipulations 
e. Using technology (ie, ACD) for preparation 
f. Anticipating incompatibilities (calcium, phosphate) 
5. Organizations should develop a strategic plan for implementation of automation and 
technology for the sterile products service. 
6. Pharmacists and pharmacy technicians shall be proficient in the proper use of technology (ie, 
ACD) when used for preparation of CSPs. 
7. State Boards of Pharmacy should create a specific license and licensing requirements for 
infusion pharmacies and compounding pharmacies. 
8. State Boards of Pharmacy should provide an in-depth training program focusing on CSPs for 
all State Board inspectors. An ongoing competency assessment program should be included 
in the training as well.  !
Rationale !
The lack of standardized training emphasizing foundational concepts behind sterile compounding 
and aseptic technique is startling in today’s professional programs educating both pharmacists 
and pharmacy technicians. Over the past 5 years, numerous reports of serious morbidity and 
mortality have appeared in the lay press due to a lack of training in aseptic technique with 
preparation of sterile products. The most recent tragic events have surrounded a rare outbreak of 
fungal meningitis that was traced to several lots of the injectable glucocorticoid 
methylprednisolone acetate compounded by the New England Compounding Center. Although 
these sterile injections were intended for back and joint pain, a lack of sterile compounding 
competency has sickened hundreds of patients and killed dozens.5 Even more relevant are the 9 
deaths that occurred in Alabama during the preparation of amino acids under high-risk conditions 
and an error in sterile compounding technique. It is incumbent on pharmacists to check that all 
people involved in the oversight and preparation of CSPs obtain appropriate training and be 
evaluated on a regular basis through a competency assessment. Pharmacists would receive 
education in the physicochemical principles of pharmacy and practice experiences as part of a 
pharmacy school curriculum. Technicians would receive education in the operations of ACD 
hardware and software with varied practice experiences as part of the curriculum. Board 
certification for those involved in CSPs could guarantee a basic minimum requirement in lieu of 
formalized training as part of a curriculum. The criteria required for nutrition support pharmacy 
board certification would suggest that these individuals are better prepared to allow fewer errors, 
although no data are available to support this contention. Anecdotal data would suggest that 
pharmacists and pharmacy technicians with specific education and many hours of hands-on 
experience are in the best position to be involved with PN compounding. In the workplace, 
pharmacists and technicians should participate in a comprehensive orientation and training 
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program with an ongoing competency assessment plan.2 This plan would evaluate all aspects of 
sterile compounding from calculations to the proper use of technology. !
Question: Compounding 3 (C3) !
(C3) How can organizations avoid PN errors by implementing soft and hard limits on an ACD? !
Recommendations !
1. Organizations shall implement specific computerized soft limits and hard (catastrophic) 
limits for PN ingredients based upon pharmacists’ review that are consistent with the needs 
of their patient population. 
2. Access to the ACD database is limited to select individuals qualified to manage and maintain 
this activity and all changes are traceable. Pharmacists and technicians shall be educated on 
interpretation and limitations of calcium-phosphate compatibility curves in the software. 
3. Weight-based warning limits for doses shall be developed by clinicians with the assistance of 
the vendors. As an alternative, organizations may develop and use their own weight-based 
warning limits. 
4. Only pharmacists shall be allowed to override alerts. An independent double-check process 
should be completed by another pharmacy staff member, ideally another pharmacist.2 
5. Healthcare organizations should check that all unresolved ACD alerts encountered during the 
PN order entry process should be presented to the person reviewing the order entry so they 
can also view and respond to the alerts. 
6. Healthcare organizations shall reinforce the importance of reacting to the ACD alerts and 
documenting all interventions. 
7. Healthcare organizations should review available reports detailing the frequency of overrides 
as well as the frequency of overrides for specific PN components. !
Rationale !
Limits can be placed on the doses of each PN component to optimize safety within the 
compounding process. These limits can be automated within the PN order-prescribing, 
reviewing, and/or compounding process. The term “hard limits” refers to alerts that indicate that 
a component is outside a determined safe range and shall not be exceeded; these are also referred 
to as “catastrophic” given patient outcomes if exceeded.2 “Soft limits” refer to alerts that indicate 
an unusual dose that requires further evaluation. Once addressed, any alert that is overridden or 
any dosing that is revised will require documentation of the rationale. Compared with manual 
methods, the software application available with ACDs should lead to improved compounding 
accuracy, enforcement of proper compounding sequence, and a reduction in opportunities for 
human touch contamination. However, preparing PN admixtures with an ACD is not an error-
free process. Error rates in compounding complex preparations such as PN admixtures have been 
reported to be 22% when automated in part and 37% when manually prepared.6 Organizations 
may improve the safety of using PN compounding systems by requiring that all doses being 
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compounded pass through an order entry/clinical decision support system and by ensuring that 
those systems’ clinical decision support features are properly enabled and configured. 
Transcription of PN order data from an order-calculating software package into a compounding 
device should be avoided. In a recent survey on PN use, Boullata et al found that dose limit 
warnings were active in only two-thirds of organizations that used ACDs for preparing PN 
formulations.7 ISMP Medication Safety Alerts from 2007 and 2011 described incidents in which 
adverse outcomes resulted, in part, from the absence of dose limit warnings.8,9 In both instances, 
infants received lethal doses of a micronutrient (zinc in one case, sodium in the other) when a 
manual order entry error was either not detected by the existing dose limits or dose limit alerts 
were not active. After reviewing the incidents, ISMP made a number of safe practice 
recommendations. Among these was the recommendation to install, test, and maximize 
automated dose-limit warnings in the pharmacy computer system and the ACD order entry 
system, particularly for high-alert medications such as PN and its ingredients. Further, ISMP 
recommends that each organization develop weight-based dosing limits applicable to their 
patient populations, as ACD vendor-established “catastrophic” limits may still allow entry of a 
potentially fatal dose into the software without issuing a warning.8,9 !
The ASHP guidelines on the safe use of ACDs for the preparation of PN admixtures state that the 
pharmacy department should develop a monitoring and surveillance plan that promotes safe and 
efficacious use of the device at all times.10 This plan should include a review of dose-limit alerts 
and overrides, utilizing the reporting capabilities of the ACD or pharmacy computer system. !
DeBoer and Maddox described a review of smart pump data after implementation throughout the 
Sanford USD Medical Center.11 Three to six months of smart pump data were collected for each 
unit and an analysis of edit variance detail and override variance detail was performed. After the 
initial review was completed, data were analyzed for medications included in the ISMP high-
alert medication list. Work practices were evaluated and revised with the goal of encouraging 
fewer edits and overrides. In a similar fashion, data from the ACD or pharmacy computer system 
should be regularly reviewed in the assessment of trends and other long-term measures of 
performance. !
Question: Compounding 4 (C4) !
(C4) What role does United States Pharmacopeia (USP) Chapter <797> play in preventing PN 
errors? !
Recommendations !
1. Healthcare organizations shall comply with USP Chapter <797> standards.12 
2. Outsourcing should be considered as an alternative to in-house compounding when the 
healthcare organization does not possess the technological resources or staffing to prepare 
PN admixtures according to USP Chapter <797>. The decision to outsource should require 
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that the pharmacy outsourcing PN production exercise due diligence to monitor that the 
outsourcer also operates within USP <797> guidelines. 
3. Standardized, commercially available PN products may be viable options to manually 
compounded sterile PN products when compliance with USP Chapter <797> and accepted 
guidelines from patient safety organizations is not feasible. 
4. Healthcare organizations shall have policies and procedures that address using multichamber, 
standardized, commercial PN products within their formulary. 
5. Healthcare organizations shall have well-defined policies and procedures that guide the 
preparation of PN admixtures. 
6. Healthcare organizations must identify standardized workflow processes that include quality 
control, process change control, and documentation practices. These standardized operating 
procedures should encompass the entire compounding process from order entry to 
verification of the final labeled product. 
7. Healthcare organizations should develop a strategic plan to include technology/automation 
for sterile compounding and consider using IV workflow software.2 
8. When an ACD is used to prepare PN admixtures, policies and procedures shall be developed 
that address performance requirements and responsibilities, control of the ACD in daily 
operations, safety and efficacy features, quality assurance monitoring and documentation, 
storage and inventory, education and training, and device variability and maintenance. 
9. Privileges to make changes in the ACD database shall be restricted to a limited number of 
pharmacy staff who are well trained in both the theory and the mechanics of this process.2 
10. Customized order entry templates created by organizations should have a documented 
standard review process by qualified staff person that includes review and testing of the 
clinical decision support that is expected to alert the pharmacist to significant warnings. The 
use of a checklist or sign-off sheet shall be required and two staff members, including at least 
one pharmacist, shall sign off on or validate the template.2 
11. The additive sequence in compounding shall be optimized and validated as a safe and 
efficacious method. Manufacturers of ACDs shall provide an additive sequence that 
promotes the safety of the compounding device. This compounding sequence should be 
reviewed with the manufacturer of the PN products used by the organization.13 
12. The use of a checklist or signoff sheet shall be required when adding new products, including 
new and alternative generics, changes in vial size or concentration, and when making other 
modifications to the ACD database (eg, changes in privileges, changes in data requirements). 
Two staff members shall be required to sign off on or validate changes. (This process would 
not apply to inputting a new lot number for a product already in the database.)2 
13. Barcode verification shall be used to verify product identity during ACD setup and 
replacement of ingredients.2 
14. An independent double-check process for the initial daily ACD setup shall be performed by 
two staff members using a printed checklist. Verbal affirmation should take place to validate 
placement of all additives and base solutions, including name, concentration, and container 
size.2 When the vendor of the compounding system describes a validated system for proper 
setup, that system should be followed. 
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15. Tubing set(s) shall be traced from the source container to the port where it is attached during 
the initial daily ACD setup and with each change in the source container.2 
16. If multiple containers of a single additive are used during the preparation of a single CSP, all 
empty containers shall be presented to the pharmacist and verified as part of the final check 
process prior to dispensing the final CSP.2 
17. When an ACD is used, it should deliver all ingredients. Manual compounding should only be 
used: 
a. If the volume of a PN component to be mixed is less than the ACD can accurately 
deliver. 
b. If there is an interaction between a PN component and a component of the ACD (eg, 
insulin and tubing). 
c. If there is a chemical interaction between PN components that cannot be mitigated by 
sequencing the addition of ingredients. 
d. During a shortage of a specific PN component, manual compounding can be a 
consideration as part of conservation efforts. 
18. Verification of manual additives should include inspection of the actual vials and syringes 
that contain the additives.9 Proxy methods of verification (eg, syringe pullback) shall not be 
used.2 
19. If the manual method is being used, the process should be standardized to promote safety 
and efficacy.13 The use of a checklist or sign-off sheet shall be incorporated into the manual 
process. 
20. PN orders should be prescribed, transmitted, and compounded when supported by properly 
trained personnel who regularly perform this task.9 This is usually during the daytime hours.  
21. In facilities that care for adult, pediatric, and neonatal patients, the preparation of CSPs for 
each population shall be separated by time or location. Separation strategies can include the 
use of different colored bins for assembling products to be prepared.2 
22. At least three verification processes should occur in the pharmacy: (1) after initial order 
entry of PN, (2) before manually injecting additives into the PN, and (3) once the PN has 
been compounded.9 In-process or end-product testing requires that the PN preparation be 
held pending results. It may be better to fully automate and validate the entire PN 
compounding process to prevent errors from being made in the first place. 
23. Organizations should develop a drug conservation policy that addresses the handling and 
disposition of PN components (while maintaining their integrity and sterility) that may be in 
short supply due to market conditions, as these shortages can affect workflow conditions. 
24. The physical environment in which PN compounding takes place should be assessed in terms 
of lighting, interruptions and distractions, sound and noise, ergonomics, and medication 
safety zone. USP General Chapter <1066> describes optimal physical environment standards 
that promote safe medication use throughout the medication-use process.14 Any deficiencies 
should be addressed following organizational chain of command. 
25. Once a standardized process for compounding PN has been implemented, organizations 
should review and revise the process on an annual basis along with a review of personnel 
compounding behavior. 
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26. Operation of the compounding process must be routinely observed for procedural 
compliance and corrective action must be taken immediately if noncompliance is observed.  !
Rationale !
An ASHP national survey of pharmacy practice in hospital settings published in 2012 found that 
overall, 65% of hospital pharmacy departments reported having a United States Pharmacopeia 
(USP) Chapter <797> compliant cleanroom.15 Having a USP Chapter <797> compliant 
cleanroom differed significantly by hospital size, with more than 87.5% of the largest hospitals 
(600 or more staffed beds) having a compliant cleanroom, compared with 48.1% of hospital 
pharmacy departments in hospitals with fewer than 50 beds. Commercially available PN 
multichamber bags were used by 36% of hospitals as the predominant form of PN formulation. 
ACDs were used by 20.4% of hospitals, followed by gravity methods (17.4%) and outsourcing 
compounding activities (14.6%); 11.6% of hospitals did not prepare PN formulations. The 
method of preparing PN differed significantly by hospital size. Larger hospitals most commonly 
used ACDs or outsourced preparations. Hospitals with fewer than 50 staffed beds most 
commonly used commercially available dextrose/amino acid formulations or TNA did not 
prepare any PN admixtures or used gravity methods to prepare PN.15 !
Organizations should refer to a number of available guidelines and articles regarding 
standardization of the PN compounding process (see Table 2). Organizations compounding PN 
admixtures must have well-defined policies and procedures to guide each step of preparation and 
shall comply with standards set forth in USP Chapter <797>.2 Compounding PN “as usual” is no 
longer acceptable if it does not comply fully with USP Chapter <797>.18 Error rates in 
compounding complex preparations such as PN admixtures have been reported to be 22% when 
automated in part and 37% when manually prepared.6 Error rates of 24% in PN preparation were 
identified in a prospective observational study.19 Compounding errors that result in an 
unexpected patient event occur in 30% of hospitals.6 The USP chapter that describes the 
compounding of sterile preparations provides minimum practice and quality standards based on 
current scientific information and best sterile compounding practices.12 Organizations that are 
unable to comply with USP Chapter <797> and accepted guidelines from patient safety 
organizations should consider alternative compounding options such as outsourcing or 
standardized commercially available PN products. !
Policies that require prescribers to order PN daily before a specified deadline should be 
established and enforced to maximize the safety with which these admixtures are prepared and 
dispensed. Pharmacy staff should be aware of all patients who are receiving PN and check if 
orders have not been received by the established deadline. PN ingredients considered to be very 
small volumes that staff manually prepare, check, and inject require verification, including 
inspection of the vials and syringes containing such additives. Verification of manual additives 
should include inspection of the actual vials and syringes that contain the additives. Proxy 
methods of verification such as the syringe pull-back method of verification should not be used 
in the preparation of PN and other high-alert CSPs and shall not be used without the presence of  
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Table 2. Documents Discussing the Standardization of the Parenteral Nutrition Preparation Process. !
Source Title    Publisher Publication Year  Reference Number !
USP Chapter <798> — “The objective USP  2006   12 
of this chapter is to describe conditions  
and practices to prevent harm, including  
death, to patients that could result from 
the following: (1) microbial  
contamination (nonsterility) (2)  
excessive bacterial endotoxins, (3)  
variability in the intended strength of  
correct ingredients that exceeds either  
monograph limits for official articles  
(see ‘official’ and ‘article’ in the General  
Notices and Requirements) or 10% for 
nonofficial articles, (4) unintended 
chemical and physical contaminants, and 
(5) incorrect types and qualities of 
ingredients in Compounded Sterile 
Preparations (CSPs).” 
ISMP Sterile Preparation Compounding ISP  2013   2 
Safety Summit Proceedings 
A.S.P.E.N. Statement on Parenteral  A.S.P.E.N. 2007   16 
Nutrition Standardization 
ASHP guidelines on the safe use of  ASHP  2000   10 
automated-compounding devices for the 
preparation of parenteral nutrition 
admixtures 
Safe Practices for Parenteral Nutrition A.S.P.E.N. 2004   13 
Compounded vs standardized commercial A.S.P.E.N. 2012   17 
parenteral nutrition products: A.S.P.E.N. 
Parenteral Nutrition Safety Summit !
ASHP, American Society of Health-System Pharmacists; A.S.P.E.., American Society for Parenteral and Enteral 
Nutrition; ISMP, Institute for Safe Medication Practices. !
the actual original source containers (medication and diluent).2 Independent double-checks 
should be incorporated into the compounding process. At least three verification processes 
should occur in the pharmacy: (1) after initial order entry of PN, (2) before manually injecting 
additives into the PN, and (3) once the PN has been compounded. Each step in the verification 
process should require a pharmacist to compare the actual prescriber’s order to the printed labels, 
and the printed labels to the additives and final product, as appropriate. Verification of manual 
additives should include inspection of the actual vials and syringes that contain the additives. The 
final verification of the compounded PN should include a comprehensive review of the PN order, 
the label on the product and the compounding work label, and a visual inspection of the CSP. 
Quality control checks and verification of replacement components on the compounder either 
manually or via barcoding should also be required, as should an independent double-check of 
any calculations.9 !
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PN multichamber bags, which are designed to reduce the risk for instability or precipitation, are 
available. These multichamber bags separate components of the PN formulation with a bar or 
seal until just prior to activation and administration. The contents of the chambers should be 
mixed and any additives introduced by pharmacy staff prior to dispensing the formulation. 
However, if these products are used in home care, patients and/or caregivers shall be provided 
with thorough training regarding the procedure for properly mixing the product before use. In 
addition, the containers should be accompanied by auxiliary labels alerting users to the need to 
mix the product prior to administration. !
Organizations should review and revise the PN compounding process on an annual basis. A 
number of analytical methods have been applied to another high-risk complex compounding 
process, such as the preparation of chemotherapy. Bonan et al describe a multidisciplinary team’s 
application of the Hazard Analysis and Critical Control Points method to preparation of 
anticancer drugs.20 The team identified 11 critical points. Monitoring, control measures, and 
corrective actions were identified for each risk. Over a 10-month period, 16,647 chemotherapy 
preparations were compounded with 1157 nonconformities for the 11 critical control points. 
These included 693 compounding sheet errors and 131 analytical nonconformities. Aboumatar et 
al reported the outcomes of application of Lean Sigma solutions to the chemotherapy preparation 
process.21 Once mistake-proofing interventions were introduced via workspace redesign, process 
redesign, and developing standard operating procedures for pharmacy staff, reported medication 
errors reaching patients causing an increase in patient monitoring decreased and the number of 
reported near misses increased. These improvements would be welcomed in the PN use process. !
Topics for Further Research !
1. The impact of the educational level and training of sterile compounding personnel on PN 
compounding error rates. 
2. The impact of State Boards of Pharmacy inspections on PN compounding error rates. 
3. Impact of the sequence for adding macronutrients, micronutrients, and non-nutrient 
medications on PN stability and compounding error rates. 
4. Impact of multichamber PN admixtures (commercially available vs customized 
compounded) on stability, including risk of precipitation. 
5. The impact of standardized, commercial PN products vs customized compounded PN 
admixtures on infections, stability, and preparation errors. !
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Parenteral Nutrition Administration !
Background !
Because PN administration errors occur at the point of patient contact, mistakes in this phase of 
the medication delivery process are less likely than other types of PN errors to be intercepted and 
more likely to cause harm. In addition, the broad range of healthcare settings in which PN 
administration takes place—from critical care to home care—raises the potential for disparities 
to exist in the technology, equipment, and knowledge and skills of the nursing staff and 
caregivers responsible for PN administration. Although once uncommon, PN is administered 
with increasing frequency in long-term care and skilled nursing facilities. Regardless of the 
setting or the number of patients receiving the therapy in a given facility, the classification of PN 
as a high-alert medication requires healthcare organizations to develop evidence-based policies 
and procedures designed to promote safe PN administration and to validate the competence of 
those responsible for delivering this complex form of IV therapy. !
Question: Administration 1 (A1) !
(A1) What system-based measures can organizations implement to enhance the safety of PN 
administration? !
Recommendations !
1. Written policies and procedures shall be developed to standardize nursing practices for the 
administration of PN throughout the organization. 
2. Education and competency assessment shall be provided to newly hired nurses and patients 
or caregivers who are responsible for PN administration. 
3. Healthcare organizations should conduct ongoing validation of competency in PN 
administration based on changes in practice related to PN administration, results of 
medication error monitoring, and/or the vulnerability of the patient population (eg, high 
acuity patients, including neonates and the critically ill). 
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4. Healthcare organizations that provide nursing services related to home infusion shall 
establish mechanisms for periodic reassessment of knowledge and techniques used by patient 
or caregivers for home PN. 
5. Interdisciplinary quality improvement programs shall incorporate analysis of medication 
errors associated with PN administration and knowledge of errors that occur in other 
institutions. 
6. Safeguards shall be implemented to address specific problem areas as indicated by analysis 
of PN administration errors. 
7. An interdisciplinary process should be employed for selecting and evaluating equipment and 
technological aids, such as smart pumps and barcoding to reduce errors in PN administration. 
8. Healthcare organizations shall develop policies and procedures that address extravasation of 
PN formulations. 
9. Acute care facilities should establish a policy that prohibits the use of a PN formulation 
prepared for administration at home or in subacute or long-term care facilities. 
10. Protocols for safe operation of infusion pumps shall stipulate rules regarding alarm silencing, 
modification, and disabling. 
11. Healthcare organizations should purchase infusion pumps with capacity to reduce errors due 
to incorrect programming. Whenever possible, infusion pumps should be standardized 
throughout the organization.  !
Rationale !
Data pertaining to the incidence of errors related to PN administration are scarce. A recent survey 
revealed that 44% of organizations do not track PN-related medication errors and do not know 
where in the process errors may be occurring.1 The literature does provide some insight into the 
scope of the problem. In particular, the frequency with which case reports of PN-related errors 
involve neonatal and pediatric patients suggests that this population may be most vulnerable to 
PN administration errors.2 !
One prospective observational study of errors associated with PN found that 35% of PN-related 
errors occurred during the administration process.3 In a similar audit of 18,588 PN days in a 
tertiary pediatric hospital, administration-related errors accounted for 30% of all PN errors.4 In 
addition, data gathered over a 5-year period from a national medication error–reporting program 
revealed 266 errors associated with IVFE in neonatal intensive care units, 93.2% of which 
occurred in the administration phase.5,6 Another report of quality improvement data from a single 
39-bed unit caring for neonates to young adults indicated that in one 6-month period, PN and 
IVFE errors accounted for 25% of all medication errors.7 !
Standardized Procedures and Competency Validation 
Failure to follow established procedures plays a prominent role in PN administration errors.2 
While human factors frequently contribute to PN errors, organizational efforts to strengthen the 
safety of PN administration must extend beyond a focus on individual performance and center on 
identifying system-based approaches to reduce errors.8,9 Fundamental to this process is the 
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development and articulation of nursing policies and procedures for PN administration that 
standardize nursing practices based on published clinical guidelines.2,5,10 These policies and 
procedures shall be reviewed and revised on a regular basis. Table 3 provides an outline of 
essential components of nursing procedures for safe PN administration. !
Healthcare organizations, regardless of setting (acute care to home care), shall conduct ongoing 
education of nurses and patients or caregivers and establish mechanisms to validate competence 
in PN administration. At a minimum, competency validation should occur in the following 
circumstances: as part of orientation for newly hired nurses, when a change in protocol or 
procedure takes place, with the introduction of new equipment or technology, and when quality 
improvement monitoring or other data sources reveal a gap in skills or knowledge related to PN 
administration.11 Home infusion nursing care providers shall establish processes for periodic 
reassessment of knowledge and techniques used by patients or caregivers in the delivery of PN in 
the home.12 Studies of educational initiatives aimed at reducing intravenous medication errors 
have not consistently produced the desired impact on error rates.13 The optimal strategy 
(simulation, case scenarios, observation, etc) for providing continuing education aimed at 
reducing medication errors remains unclear, emphasizing the importance of using a variety of 
educational strategies and maintaining vigilance in evaluating their effectiveness. !
Policies and procedures related to PN administration should address management of 
extravasation of PN formulations into perivascular or subcutaneous tissues.14-18 Although most 
often associated with peripheral vein infusions, PN extravasation can occur with all types of 
vascular access devices (VADs).11,17 A number of factors influence the extent of tissue damage, 
including pH, osmolarity, electrolyte content, and duration of tissue exposure.17 No controlled 
trials are available for the management of PN extravasations, but consensus-based 
recommendations include stopping the infusion, aspiration of residual fluid, elevation of the 
limb, and application of cold therapy.11,17 Treatment with hyaluronidase has also been described 
for extravasations of PN and hypertonic dextrose.17,19 Education for nursing staff and nutrition 
support clinicians should include ongoing assessment of the vascular access site and appropriate 
interventions in the event of an extravasation. !
Organizations must also develop policies pertaining to the administration of PN formulations 
brought in from home or from another facility. The inability to verify the stability and sterility of 
the formulation—as required by The Joint Commission standards—raises serious safety 
concerns.20 The lack of medical and pharmacy review can potentially lead to the infusion of 
compromised PN formulations or prescriptions that are not appropriate for the patient’s current 
clinical status. Accordingly, 75% of organizations currently prohibit the use of preparations 
brought from home.1 !
Role of technology 
Technological advances hold much promise for improving the safety of PN administration. Yet 
only 33% of healthcare organizations report using CPOE for PN orders, while 20% employ 
barcode medication administration (BCMA).1 Little evidence is available regarding the impact 
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Table 3. Essential Components of Nursing Policies and Procedures for PN Administration. !
A. Role responsibilities, delegation considerations 
B. Required equipment 
C. Verification procedures 
1. Confirmation of patient identity according to organizational policy 
2. Use of PN formulas prepared in another institution 
3. Checking PN label against the order including formulation components, route, and rate of delivery, 
expiration date 
4. Inspection of formulation to detect defects or visual changes 
5. Verification of appropriate vascular access prior to initiating PN infusion 
• Tip location: newly inserted lines and those in place on admission 
• Safeguards to avoid tubing misconnections—trace tubing to the body before making the connection 
• Confirm patency 
D. Administration 
1. Policy regarding verification of pump settings 
2. Observation of formulation integrity during infusion 
3. Importance of maintaining PN infusions at the prescribed rate—avoid interruptions for routine care or 
adjustments for infusions that are off schedule 
4. Guidelines for medicating administration for patients receiving PN 
• Policies for co-infusing IVFE or other medications with PN 
• Policies prohibiting additions to PN formulations on clinical units 
5. Recognizing a compromised PN formulation 
6. Significance of clogged filters 
E. Infection control measures 
1. VAD dressing care procedures, aseptic management of catheter hub 
2. Frequency of tubing and filter change 
3. Hang time 
4. Minimizing manipulations 
• Dedicated line, lumen 
• Blood-drawing practices 
F. Monitoring 
1. Appropriate blood glucose monitoring based on clinical condition and infusion schedule (cycled vs 
continuous infusion) 
2. Laboratory monitoring 
3. Evaluating response to therapy 
4. Recognition and intervention for extravasation 
G. Complications and troubleshooting 
H. Termination of therapy 
I. Patient education 
J. Documentation !
of these technological aids in reducing errors in the PN administration process. CPOE appears to 
offer benefits in preventing errors in the prescription and transmission phases rather than those 
associated with PN administration.21-23 BCMA technology serves as an aid in verifying patient 
identity, but errors can occur when clinicians bypass the safety features of the system. Complex 
admixtures such as PN present challenges with BMCA systems because current technology 
cannot validate that the label on a formulation containing multiple ingredients accurately reflects 
the contents of the PN container. !
Infusion pumps have long been seen as a requirement for PN administration.2,11 Yet despite their 
widespread use as a safety measure, pump-related mishaps stand out as a frequent factor in PN 
administration errors.4,6 At a minimum, infusion pumps should feature accurate volume (rate 
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control), anti–free flow controls, and alarms for sensing air and pressure changes in the 
administration tubing, as well as dose error reduction software.11,24 Protocols for safe operation 
of infusion pumps shall stipulate rules regarding alarm silencing, modification, and disabling. !
In recent years, infusion pumps equipped with software designed to detect potential errors 
(“smart pumps”) have become available, although conflicting information exists regarding the 
use of these devices. A recent gap analysis that specifically addressed current PN practices found 
that smart pumps are available in 29% of responding facilities.1 On the other hand, a survey of 
hospital-based pharmacies reported a usage rate of 77% for these devices.22 Smart pumps 
provide a safeguard against programming errors and capture data that can support quality 
improvement programs.25 When used properly, smart pumps reduce the potential for error, but 
this pump technology is not foolproof. If a smart pump drug library is bypassed or is used 
incorrectly or the infusion rate and volume are manually entered, a dose error can occur. One 
case study, for example, reported an incident in which a PN infusion was administered at 10 
times the prescribed rate for 2 hours when a soft limit alert was bypassed.26 The advantages of 
smart pumps can be offset by the complexity of programming the pumps and maintaining a 
current drug library. To have a meaningful impact on patient safety, smart pumps must be 
integrated with BCMA and CPOE systems as well as hospital and pharmacy information 
systems.21 A comprehensive organizational commitment to the technology of smart pumps is 
essential to the successful deployment in clinical areas.25,27 Organizations should purchase 
infusion pumps with capacity to reduce errors due to incorrect programming. Whenever possible, 
infusion pumps should be standardized throughout the organization to promote user familiarity 
with the operation of the device.28 !
Quality improvement 
A critical step in efforts to improve the safety of PN is the implementation of quality 
improvement programs designed to track and analyze errors associated with PN administration.8 
However, only 39.9% of organizations report having an ongoing quality improvement process 
for PN.1 Proactive and reactive methodologies, failure mode effects analysis, root cause analysis, 
and the Plan-Do-Study-Act (PDSA) model should all serve as the framework for identifying high 
occurrence or high impact errors, closing practice gaps, and engendering continuous process 
improvement.29,30 Multifaceted interdisciplinary approaches must foster a culture of safety, 
clarify problem areas, involve key stakeholders, test change strategies, and maintain channels of 
communication. These key concepts are most effective in bringing about and sustaining behavior 
change.29 !
As noted earlier, smart pumps can serve as a valuable source of quality improvement data that 
allows organizations to track practices related to PN administration and identify interventions 
that address safety breaches.25 However, without a reliable wireless network, data retrieval can 
be labor intensive.25,27,31,32 !!!
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Question: Administration 2 (A2) !
(A2) What strategies can prevent errors in the verification phase of PN administration? !
Recommendations !
1. The verification process of PN administration should be presented in a bundle format, which 
uses a set of evidence-based interventions for a defined patient population or care setting. 
2. Nurses, caregivers, and patients shall visually inspect the integrity of the PN container and 
formulation before spiking the container. 
3. The PN label shall be verified against the original prescriber order. No verbal orders shall be 
accepted. 
a. Check the patient identifiers, product name, route of administration (central vs 
peripheral), designated initiation time, infusion rate, and beyond-use date and time. 
b. Match all components listed on the label of the formulation to the PN order. 
4. A printed copy of the PN prescription shall be provided to home PN consumers initially and 
with each formulation change to allow this verification step. 
5. Patient identity shall be confirmed using two identifiers according to organizational policy. 
6. The administration tubing shall be traced to the point of origin in the body at the initiation of 
the infusion and at all handoffs. 
7. An independent double-check process and verification of infusion pump settings should be 
performed by a second clinician before beginning the PN infusion and documented in the 
medical record.  !
Rationale !
PN administration errors often stem from failure to adhere to the verification steps of PN 
administration, which parallel the “five rights” of medication safety that all nurses learn: right 
patient, right drug, right dose, right route, and right time.9,11 Policies and procedures for PN 
administration should avoid broad directives to “check the label” but instead provide clear 
procedural guidance for each step in the verification process. This verification process should be 
presented in a bundle format, which uses a set of evidence-based interventions for a defined 
patient population or care setting. As with other bundles used in healthcare, all components of 
the verification process must be implemented together to achieve improvements in care.33 !
Adherence to the “five rights” is not sufficient in preventing medication errors. Although human 
factors frequently contribute to errors, healthcare organizations have a responsibility to create an 
infrastructure that supports safe practice and reduces the potential for error.8,9 This includes 
educating staff about the proper use and effectiveness of double-checks and creating procedures 
for reporting errors, near misses, and barriers to safe practice in a nonpunitive environment.8,9 !!!
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Verification procedures 
PN formulations often resemble other products used in clinical care, such as bladder irrigation 
fluids, enteral formula, human breast milk, and cardioplegia solutions, posing the risk for wrong-
product or wrong-route errors. Practices related to the delivery and storage of these items can 
mitigate the likelihood of such errors, but the importance of the verification process as the final 
step before the point of patient contact cannot be overstated. !
Nursing education for PN administration shall include information regarding management of 
potentially compromised or unstable PN formulations. This includes inspection of PN 
formulations prior to initiating the infusion and at regular intervals during the infusion. Any 
formulation that displays evidence of precipitants, particulate matter, or an unstable formulation 
shall be returned to the pharmacy for further investigation.34 !
Other examples of lapses in the verification process include PN administration to the wrong 
patient by the wrong route—infusing a central formulation via peripheral vein or through an 
incorrect tubing connection—or at the wrong rate.2 The nurse or caregiver should be provided 
access to the complete original PN order to facilitate verification of all elements of the order (ie, 
patient identifiers, nutrient dosing, infusion rate, etc).1 !
Mistakes involving incorrect infusion rates are among the most common errors reported. Often, 
these errors are related to mistakes in programming a single infusion pump, but the risk for rate 
errors appears to increase when IVFE and dextrose/amino acid components are administered as 
separate infusions.2,3,6 Errors involving incorrect infusion rates pose the greatest risk for patient 
harm due to the potential for causing life-threatening metabolic disturbances such as 
hyperglycemia or fat overload syndrome. !
Tubing misconnections 
Inadvertent catheter tubing misconnections have been recognized as a serious problem in 
healthcare. Although the administration of enteral feeding through intravenous devices has been 
associated with the most serious injuries, accidental connections between intravenous tubing and 
other systems that rely on Luer connectors have been reported, including epidural, intracranial, 
intrathecal, and tracheal tubing systems.35,36 Because tubing used to administer PN must be 
changed every 24 hours, the potential for a misconnection occurs at more frequent intervals than 
with conventional intravenous fluids. Clear labeling on PN containers, tubing, and pump 
channels can reduce the risk of inadvertent misconnections.32,37 However, the single most 
important risk reduction strategy is to trace all tubing back to its origin before connecting devices 
or infusions and to recheck connections and trace all patient tubes and catheters to their sources 
at the start of each shift and upon the patient’s arrival to a new setting or unit as part of the hand-
off process.38,39 !
Independent double-checks 
Reports of PN-related errors often recommend implementation of independent double-checks at 
critical phases of PN administration, such as order verification or programming the infusion rate 
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into the pump.2,3,6,7,32 To be effective, an independent double-check must involve two clinicians 
separately checking the infusion settings in accordance with the prescriber’s order, alone and 
apart from each other, then comparing results.40 Although double-checks serve as a valuable 
safety mechanism if performed correctly, the process may require up to 20 minutes of additional 
nursing time.40 Other barriers include a lack of clarity regarding the procedure for double-
checking and a culture that does not fully support peer review.41 Furthermore, excessive use of 
double-checks can dilute the effectiveness of this safety mechanism.40,42 Independent double-
checks should not be implemented to address problems that could be corrected through system 
redesign.40 Nevertheless, organizations that have identified errors in conjunction with a specific 
component of the PN verification process, such as order verification, patient identification, or 
pump programming, should implement double-checks strategically to avert potentially harmful 
errors. For optimal effectiveness, independent double-checks should be used in conjunction with 
other error reduction strategies and system changes aimed at reducing the risk of medication 
errors.40 The use of computer-generated checklists with PN infusion instructions has been 
suggested as a way to guide verification procedures without increasing workload demands, but 
this approach requires further study.5,43 !
Question: Administration 3 (A3) !
What practices maintain patient safety during the infusion of PN? !
Recommendations !
1. PN shall be administered by or under the supervision of trained, competent personnel. 
2. Organizations shall establish evidence-based policies to guide the selection, insertion, care, 
and maintenance of VADs used to administer PN. 
3. PN protocols shall include measures to reduce contamination through manipulation of the 
catheter hub. 
4. VADs used for PN administration should not be used to obtain blood samples for laboratory 
tests unless no peripheral access is available. 
5. PN infusions shall be infused through a filter appropriate for the type of formulation. 
6. An occluded filter shall never be removed in response to occlusion alarms, thus allowing the 
unfiltered formulation to continue to infuse. 
7. Administration tubing should be attached to PN containers immediately prior to use. 
8. Administration tubing and filters shall be changed with each new PN container (every 24 
hours for TNAs and dextrose/amino acid formulations; 12 hours for IVFE infused 
separately). 
9. For prolonged infusions of IVFE (20–24 hours), the daily dose should be divided into 2 
parts, with a new container and tubing every 12 hours. 
10. Policies regarding PN multichamber bags should be developed using a multidisciplinary 
approach. 
11. The PN infusion shall be maintained at the prescribed rate: 
a. Correct pump settings shall be verified at regular intervals and at each hand-off. 
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b. The PN infusion rate shall not be adjusted if the infusion is off schedule. 
c. The rate of PN shall not be increased in response to changes in fluid needs; additional 
hydration should be provided as a separate infusion. 
d. The PN should not be interrupted for routine care or patient transport for diagnostic 
studies. 
e. Organizations shall develop policies regarding PN infusion and appropriate metabolic 
monitoring during surgery. 
12. The timing and frequency for blood glucose monitoring shall be based on clinical status and 
performed in a manner appropriate for the PN infusion schedule (cycled vs continuous). 
13. Caution shall be used when administering subcutaneous insulin coverage prior to a 
scheduled interruption of the PN infusion. 
14. In acute care acute settings (including long-term acute care), no additions should be made to 
PN formulations outside the compounding pharmacy; in home settings, additions to PN 
formulations should be limited in number and be made as close as possible to initiating the 
infusion. 
15. In long-term care facilities and in home care, education should be provided and caregiver 
competency regarding proper technique for the addition of prescribed additives to PN 
formulations should be verified. 
16. Co-infusion of medications through PN lines shall require a review of compatibility and 
stability data by a pharmacist. 
17. PN should be discontinued prior to transfer to another facility. 
18. The administration of PN and the patient’s tolerance shall be documented in the medical 
record. !
Rationale !
Nursing care during PN infusion centers on administering the infusion as prescribed, preventing 
complications, monitoring metabolic stability, assessing progress toward therapeutic goals, and 
documenting patient response to therapy. This process includes safe and effective management of 
all medical devices and equipment used in the delivery of PN, safe administration of medications 
in conjunction with PN therapy, and optimal care of vascular access devices. !
Medical devices and equipment 
Vascular access 
Reliable vascular access is essential for safe and effective delivery of PN. A wide array of VADs 
are available, but some are better suited to PN delivery than others. Factors that influence the 
selection of a VAD for PN include the patient’s medical condition, need for concomitant 
intravenous medication(s), the anticipated duration of PN therapy, and the setting in which PN is 
administered.11 In all care settings, the patient’s views should also play a role in the decision-
making process for VAD selection. !
Despite their essential role in PN administration, VADs are a leading cause of serious adverse 
complications related to PN therapy, in particular, central line–associated bloodstream infection 
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(CLABSI). PN is an independent risk factor for CLABSI, requiring organizations to be 
especially vigilant in establishing policies to guide the selection, insertion, and care of these 
devices.44 In recent years, widespread implementation of a bundle of evidence-based guidelines 
for insertion and maintenance of VADs has achieved substantial reductions in the CLABSI rates.
45 In addition to addressing VAD insertion and site care, PN protocols shall also include 
measures aimed at reducing contamination that occurs through manipulation of the catheter hub. 
Some organizations maintain policies requiring a dedicated line or lumen for PN administration, 
although studies have not yielded consistent results regarding the efficacy of this practice.46 !
Many organizational protocols for care of VADs discourage blood sampling from central lines as 
part of an overall effort to reduce manipulation and subsequent contamination of the catheter 
hub. For similar reasons, The Joint Commission has highlighted the use of VADs for blood 
sampling as a “practice to avoid.”47 One recent study of home PN recipients found an increased 
risk for CLABSI in patients who routinely had blood drawn from a VAD, leading these authors 
to conclude that PN catheters should not be used for obtaining blood samples unless no 
peripheral access is available.46 The elevated risk for CLABSI that is associated with PN 
administration warrants a multifaceted approach to CLABSI prevention that targets all pathways 
for VAD infection. !
The use of VADs for blood withdrawal not only increases the risk for microbial contamination of 
the line and hub, but samples drawn incorrectly from a VAD during PN infusion can also lead to 
spurious laboratory values. Binkley et al first drew attention to the danger of this phenomenon in 
a report of a 10-month quality assurance study.48 More recently, a year-long prospective cohort 
study in an academic medical center found 63 incidents of spurious blood work in 34 PN 
recipients.49 In both cases, investigators recount incidents of patient harm—typically 
hypoglycemia or hypokalemia—that resulted from unnecessary medical intervention for falsely 
elevated laboratory values. !
Filters 
In-line filters are required for PN administration to reduce the potential for patient harm due to 
particulates, microprecipitates, microorganisms, and air emboli.50 These devices should be 
placed as close to the patient as possible on the administration system. A 0.22-micron filter is 
recommended for a dextrose/amino acids formulation; a 1.2-micron filter is used for a TNA 
formulation. Because nurses must deal with the problem of pump alarms at the point of care, 
nursing competencies for PN administration shall include appropriate actions and 
troubleshooting in response to high-pressure alarms or an occluded filter. This education shall 
emphasize that a filter that becomes occluded during PN administration should raise suspicions 
that the incorrect filter size has been used or that a precipitate or particulate is present in the 
formulation. When an occluded filter triggers pump alarms, the PN infusion shall be stopped. 
Before resuming PN, a pharmacist should review the PN formulation to determine if 
incompatibility issues are the cause of the problem and to identify actions to prevent further 
occurrences. !
!54
Filters are manufactured for single patient use and should be changed according to the 
manufacturer’s guidelines. The typical maximum use interval for PN filters is 24 hours. Due to 
the potential for contamination and subsequent release of endotoxin, filters should not be primed 
with PN fluid in advance—in the compounding pharmacy, for example. Instead, the filter should 
be filled with fluid immediately before initiating the infusion. !
Administration tubing and containers 
PN formulations should be provided in a single daily bag, with the exception of IVFE that is 
administered as a separate infusion. The PN admixture should be kept refrigerated and protected 
from light exposure between the times it is dispensed until just before infusion. Exposure of PN 
formulations to ambient light generates peroxides and other degradation products, potentially 
contributing to oxidant stress. Concern regarding the clinical impact of this phenomenon has led 
to recommendations that PN be shielded from light, especially for neonates.51 However, studies 
have failed to demonstrate clear clinical benefits of shielding PN formulations from light. Partial 
light protection offers no clinical benefit. To reduce PN degradation, the container and tubing 
must be protected from light at all points from compounding through administration.52 Further 
research is required to determine if complete photoprotection of PN formulations can lead to 
improved clinical outcomes. !
The administration tubing should be attached to the PN container, using sterile technique, 
immediately prior to initiating the infusion. Although there may be workflow advantages to 
spiking the container and priming tubing in advance, no studies have examined the safety of this 
practice. Infection control guidelines for non-nutrition intravenous fluids stipulate that the 
infusion begin within 1 hour of inserting the tubing spike into the container.53 The issue of 
whether the risk of contamination could be reduced by spiking the PN container in an ISO Class 
5 environment or higher remains unknown. !
IVFE administered separately shall be appropriately labeled and administered in keeping with 
the organization’s policies and procedures for minimum/maximum hang times. PN containers 
and administration sets shall be free of the plasticizer di-2-ethylhexyl phthalate (DEHP) to 
prevent DEHP contamination of TNA formulations and IVFE that are infused separately.2,11 
Guidelines for the frequency of tubing changes for PN formulations often make a distinction 
between admixtures that contain IVFE (every 24 hours) and those that contain only dextrose and 
amino acids (no more frequently than 96 hours).11,44 However, these recommendations overlook 
the potential for contamination of the filter on all types of PN formulations. Therefore, 
administration sets and filters should be changed with each new PN container. For continuous 
infusions, this interval will typically be every 24 hours; cycled PN will require tubing and filter 
changes based on the hours of the infusion. Administration sets used for IVFE infused separately 
shall also be changed with each new infusion (hang time 12 hours). In cases in which a 
prolonged IVFE infusion is desirable to promote tolerance, the daily fat emulsion dose should be 
divided into 2 parts, with a new container and tubing used every 12 hours.54,55 !
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Multichamber PN bags are available, which are designed to reduce the risk for instability or 
precipitation. These multichamber bags separate components of the PN formulation with a bar or 
seal until just prior to administration. The contents of the chambers should be mixed and 
additives introduced by pharmacy staff prior to dispensing the formulation.56 However, if these 
products are used in home care, patients and/or caregivers shall be provided with thorough 
training regarding the procedure for properly mixing the product before use. In addition, the 
containers should be accompanied by auxiliary labels alerting users to the need to mix the 
product prior to administration.57 !
Infusion practices 
PN infusions should be administered according to the prescribed rate via an infusion pump. 
Nurses shall verify the correct rate when the PN infusion is initiated, at regular intervals during 
the infusion, and at hand-offs.58 Scheduled changes in the prescribed administration rate should 
be based on patient tolerance and metabolic stability. In acute care settings, PN is commonly 
infused continuously over 24 hours. However, a schedule in which the PN is cycled to infuse 
over 10 to 14 hours (based on patient tolerance) can offer physiologic and psychological benefits 
to patients in selected circumstances.59,60 The conversion from a continuous to a cycled 
administration period typically takes place by reducing the infusion time by 4 to 6 hours each 
day until the infusion time has been compressed to the target duration. However, one recent 
study suggests that cycling PN to 12 hours can be accomplished in one step.61 A report 
documenting a high incidence of adverse events associated with PN cycling underscores the 
importance of close patient monitoring during the transition to cycled PN.60 At each stage, the 
healthcare team must assess tolerance of the cyclic infusion before advancing to the next step. !
Hyperglycemia, edema, or symptoms of fluid intolerance signal the need for a more cautious 
approach to cyclic infusion. Adult patients tolerate abrupt discontinuation of PN without 
experiencing rebound hypoglycemia.62 However, a 30- to 60-minute taper-down period is 
customarily used with ambulatory PN infusion pumps that perform this function automatically.63 
On the other hand, pediatric patients younger than 2 or 3 years old are prone to developing 
hypoglycemia with abrupt discontinuation of PN and therefore require more gradual taper-down 
procedures in conjunction with cycling.59,60 During the transition to a cycled PN regimen, on-
cycle and off-cycle glucose monitoring should take place daily. Once patient tolerance to cycled 
PN is established, less frequent glucose monitoring may be acceptable, especially in stable home 
PN patients.64 !
When transitioning to cyclic PN, dosing regimens for insulin should be tailored to avoid 
abnormal fluctuations in blood glucose levels. In patients for whom PN is the sole source of 
nutrition, giving subcutaneous correctional dose insulin in the final phase of the cycle could lead 
to hypoglycemia when the PN infusion is discontinued. On the other hand, when PN 
formulations contain large doses of insulin, patients may require intermediate or long-acting 
insulin to prevent hyperglycemia after the PN stops. !
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Unscheduled interruptions in the infusion should be avoided because they may contribute to 
metabolic disturbances and suboptimal nutrient delivery. PN administration should not be 
interrupted for medication administration.4 PN should be discontinued prior to discharge or 
transport to another facility. As noted earlier, a taper-down period is a gradual reduction in the 
PN rate. Adult patients do not require a taper; however, a taper period for pediatric patients 
receiving PN prevents rebound hypoglycemia. !
The risks of metabolic complications, particularly those related to glycemic control, have raised 
questions regarding the safety of continuing PN during operative procedures. However, no 
studies have adequately examined this issue. One survey of pediatric anesthesiologists revealed a 
high degree of variability in the clinical management of blood glucose levels in patients 
receiving PN during anesthesia.65 As with other areas of PN administration, healthcare 
organizations should develop clear and consistent policies that address intraoperative PN 
infusion. When the PN infusion is continued during surgery, the prescribed infusion rate should 
be maintained, with close monitoring of blood glucose levels and insulin administration as 
needed to maintain glycemic control. The use of PN infusions for fluid resuscitation shall be 
avoided. !
Medication administration 
Historically, PN formulations were viewed as convenient vehicles for delivery of medications 
such as heparin, insulin, and histamine (H2) receptor antagonists. However, a better 
understanding of factors that impact the stability of PN formulations and the potential for drug-
nutrient interactions warrants a more conservative approach to medication administration with 
PN formulations. The mixture of medications in PN preparations is being addressed more 
specifically in A.S.P.E.N.’s forthcoming parenteral nutrition clinical guidelines, which are to be 
published in the near future. Incompatibility reactions range from discoloration, degradation of 
nutrients or medication, and formation of precipitates, to loss of emulsion integrity in TNA 
formulations. The greatest risk for incompatibility exists with medications that are added directly 
to the PN formulation due to the prolonged time of contact between the medication and PN 
components with direct admixtures.66 Standardized commercial PN products that require further 
additives prior to patient administration should be prepared in the pharmacy under aseptic 
conditions. Therefore, in acute care settings, policies shall be implemented that prohibit the 
addition of medication outside the compounding pharmacy. However, in home care settings, 
stability considerations often require that medication, such as multivitamin preparations or 
insulin, be added to PN formulations prior to initiating the infusion. In this case, the addition of 
medication should take place as close to the beginning of the infusion as possible. Patient and 
caregiver training in the proper technique for adding medication to PN formulations shall be 
documented. The additions should be made as close to the beginning of the infusion as possible 
to reduce the potential for harm should touch contamination occur during this process. !
As noted earlier, the optimal way to administer PN is through an IV line (one lumen of a 
multilumen VAD) reserved solely for that purpose. However, maintaining a dedicated line for PN 
administration may be impractical or impossible in patients who receive multiple IV medications 
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or have limited vascular access.2 Pharmacists must conduct a comprehensive review of stability 
and compatibility data from the literature and manufacturer of intravenous nutrients before a 
medication is administered in a PN formulation. !
As with all high-alert medications, PN should be administered as a primary infusion.37 Co-
infusion of medication through the same tubing used for PN should also be avoided if possible. 
Compatibility information should be derived for PN that closely matches the formulation in 
question. Medication administration policies should explicitly detail safe practices with regard to 
medication administration in conjunction with PN. !
Documentation 
Organizational policies and procedures shall define documentation practices related to PN 
administration in accordance with legal and regulatory requirements. This should include, but is 
not limited to, initiation and discontinuing times of the infusion, rate, route of administration, 
results of capillary glucose monitoring and laboratory tests, condition of the VAD, patient’s 
response to therapy, progress toward therapeutic goals, and patient education provided. !
Topics for Further Research !
1. Identification of the optimal use of independent clinician double-checks in critical aspects of 
the PN administration process. 
2. Identification of educational strategies that are most effective in developing and validating 
competence in PN administration procedures. 
3. Demonstration of PN error reduction with routine assessment of competence in PN 
administration procedures. 
4. Identification of environmental and human factors that contribute to PN administration 
errors. 
5. Identification of strategies to mitigate the risk of PN administration errors. 
6. Evaluation of the optimal approach for managing PN during surgery. 
7. Impact on infection rates and accuracy of laboratory tests with the use of vascular access 
devices to obtain blood samples for laboratory tests. 
8. Clarification of the appropriate use of filters with IVFE administration. 
9. Evaluation of using checklists for PN administration in reducing PN-related errors. !
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Conclusion !
PN serves as an important therapeutic modality used in adults, children, and infants for a variety 
of indications. The appropriate use of this complex therapy aims to maximize clinical benefit 
while minimizing the potential risks for adverse events. Complications can occur as a result of 
the therapy, as well as the result of the PN formulation process. These consensus 
recommendations are based on practices generally accepted to minimize errors with PN therapy 
and categorized in the areas of PN prescribing, order review and verification, compounding, and 
administration. These recommendations should be used in conjunction with other A.S.P.E.N. 
publications, and researchers should consider studying the questions brought forth in this 
document. !
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Appendix 1. A.S.P.E.N. Clinical Guidelines Questions for Safe Practice Parenteral Nutrition Ordering, Order 
Review, Compounding, and Labeling/Dispensing. 
Question 
1. Does education of prescribers improve PN ordering? 
2. What is the maximum safe osmolarity of PN admixtures intended for peripheral vein administration? 
3. What are the appropriate calcium intake and the calcium-phosphate ratios in PN for optimal neonatal bone 
mineralization? 
4. What are the clinical advantages or disadvantages of commercially available premade (“premixed”) PN 
formulations compared with compounded PN formulations? 
5. What are the clinical (infection, catheter occlusion) advantages or disadvantages of 2-in-1 compared with 3-in-1 
PN admixtures? 
6. What macronutrient dosing limits are expected to provide for the most stable 3-in-1 admixtures? 
7. What are the most appropriate recommendations for optimizing calcium (gluconate) and (Na- or K-) phosphate 
compatibility in PN admixtures? 
8. What micronutrient contamination is present in parenteral stock solutions currently used to compound PN 
admixtures? 
9. Is it safe to use the PN admixture as a vehicle for non-nutrient medication delivery? 
10. Should heparin be included in the PN admixture to reduce the risk of central vein thrombosis? 
11. What methods of repackaging IVFE into smaller patient-specific volumes are safe? 
12. What beyond-use date should be used for 
a. IVFE dispensed for separate infusion in the original container, and 
b. repackaged intravenous fat emulsion (IVFE)? !
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